Yang Huiyan is no longer Asia’s richest lady, as the country’s developers, notably her Country Garden Holdings Co., are battered by China’s property crisis. Savitri Jindal, an Indian woman, who has a wealth of $11.3 billion owing to her business, the Jindal Group, which is active in fields notably metallurgy and power production, overtook Yang on July 30, 2022, in the Bloomberg Billionaires Index as Asia’s wealthiest woman. She also left behind another Chinese millionaire Fan Hongwei, whose fortune stems from the chemical-fiber firm, the Hengli Petrochemical Co.
Savitri Devi Jindal’s life path from a housewife to an industrialist with a commoner’s heart shows us the power of women. She is a true encouragement to many women who want to start their professions but are afraid to succeed. This lady has demonstrated that when it comes to her family, a woman would go to any length to defend them. This abrupt change following her husband’s death had not left her weak in her thinking but rather resolved to achieve her husband’s goal till her final breath. She is a lady to be proud of, as well as a learning opportunity that will enable many women to live prosperous and independent life.
Savitri Jindal is presently India’s tenth richest person. For the last five years, Forbes has continuously named her India’s richest woman. Savitri leads the organization so well because she is both a mother and a businesswoman at heart. As a result, “The Jindal Group” is now not only on everyone’s lips in India but has also made its mark on the rest of the world.
Read this article further, to learn about the journey of Savitri Jindal, her biography, starting from her early life, her education, her current state, and much more.
Savitri Jindal was born in Tinsukia, Assam on March 20, 1950. Savitri married Om Prakash Jindal, founder of the OP Jindal Group, in 1970. The couple has a total of nine children. After OP Jindal died in a helicopter crash in 2005, Savitri took over as CEO of the corporation.
She received her schooling in Assam, her native. She did not go to college. She received her diploma degree from Assam University.
Savitri Jindal – Family
After Vidya Devi, O.P.’s first wife and Savitri’s sister passed away, Savitri Jindal’s father arranged for her to marry entrepreneur Om Prakash Jindal when she was 15 years old. O.P., who was 20 years older than Savitri, was the father of six children from his first marriage, the oldest of whom was about Savitri’s age. O.P. and Savitri have three biological children.
In 1970, Savitri married Om Prakash Jindal. O.P. Jindal died in a helicopter crash. Her four sons are Pruthviraj Jindal, Ratan Jindal, Sajjan Jindal, and Naveen Jindal, who are in charge of the Jindal group. She has a total of nine children.
After O.P. Jindal died in a helicopter accident in 2005, his four sons received equal ownership of the group’s businesses, which they currently manage on their own. They were the driving force behind the conglomerate’s decision to list electricity company JSW Energy on the National Stock Exchange of India and to grow internationally by acquiring coal mines in Mozambique and iron ore mines in Chile. Her son Sajjan Jindal, who resides in Mumbai and oversees JSW Steel among other things, is in charge of the group’s most valuable assets. Jindal Steel & Power is managed by Jindal’s younger son Naveen, who lives in Delhi.
As a housewife – Savitri was the wife of Mr. O.P. Jindal, a well-known industrialist, and politician at the time, and the mother of nine children. Savitri Devi gained management skills by managing the household. As the heart of the Jindal family, she also had a unique ability to bring the members of the bloodline together. Despite being the wife of such a great man, Savitri Devi’s wings were always firmly planted in the ground and focused on the responsibility of looking after the family members. Her husband, Mr. O.P. Jindal, died in a helicopter mishap in North India in 2005, and this abrupt tragedy turned her life around completely.
As a businesswoman – Savitri Devi’s life had an abrupt jolt that caused her to leap to greater heights, from caring for the house to managing the business her husband, Mr. O.P. Jindal, started in 1952. The children of Savitri Jindal share equally in the ownership of the several businesses that make up The Jindal Group. Savitri Jindal rose to become one of the richest women in the world while managing the family company with the utmost care. After she took over, the company’s revenue increased exponentially.
Savitri Jindal – In Politics
She was elected to the Haryana Vidhan Sabha from the Hissar constituency in 2005. Following her election in 2009, she was once again re-elected to the district on October 29, 2013. She served in the previous administration as the Minister of State for Emergency Management, Restructuring, Reconstruction, and Housing as well as Local Urban Bodies and Housing.
As a minister in the Haryana Vidhan Sabha, Savitri represents the Hisar Constituency. Savitri lost a lot of seats in the 2014 Haryana Assembly elections. She became the Jindal group’s Chairperson upon her husband’s death. She was also a member of the Indian National Congress political party. She is one of the richest women and one of the top 10 richest businesspeople.
In 2013, he was appointed as a Cabinet Member of the Haryana Government.
In 2014, he was a member of the Haryana Legislative Assembly.
Asia One Magazine will bestow an international accolade in the field of women’s empowerment in 2021.
The tenth richest person in India and Asia’s richest woman
Savitri Jindal – Social Work
Aside from politics and business, this lady, with a touch of simplicity, focuses on social concerns. She entered the field of social care to accomplish her husband’s desire of improving the quality of life of the poor, farmers, and laborers, as well as to speak for youth and women. She says that she is determined to serve the social cause till her last breath.
Savitri Jindal – Controversies
Savitri Jindal filed a complaint against the CEO of ZEE News, Samir Ahluwalia, and other top ZEE News employees before the Election Commission of India in 2014, citing the circulation of fake news on the channel and harming her professional image.
During an election rally in the Hisar region on 14 October, Subhash Chandra made an unfair, false, deceptive, and defamatory statement about members of the Jindal family, namely against the plaintiff (Savitri Jindal) and Congress MP Naveen Jindal.
Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Divi’s Laboratories.
Medicines, or drugs, or tablets, cough syrups, or pills, have become a part of our everyday lives. Have you ever thought about what would have happened if medicines were never discovered? Scary to think, right? because how else we would survive without treating different illnesses, or diseases?
Things were very different before 1800 as to how humans used to treat and prevent diseases. Although it’s tough to put so much information in one go, we can say that the first pharmaceutical medication was produced in 1804 by Friedrich Sertürner, a German scientist.
The establishments and inventions with curious methods of preventing many diseases provoked a lot of discoveries. As a result, the pharma industry was born with a lot of organizations indulging in manufacturing and producing drugs and medicines.
Divi’s Laboratories with its headquarters in Hyderabad is an Indian global Pharmaceuticals company founded in 1990 by Dr. Murali Krishna Prasad Divi. The company is regarded as one of the top pharmaceutical companies for ‘custom synthesis’ and also as India’s second most valuable pharma company.
Want to know what makes the company a custom manufacturer? then please do give a read to this article, where we cover details of Divi’s Laboratories’ success journey, who are its founders, its mission & vision, products and services offered by Divi’s Lab, its business and revenue model, what are its plans for the upcoming future and much more interesting information.
Divi’s Laboratories – Company Highlights
Headquarters
Hyderabad, India
Sector
Pharmaceuticals
Type
Public
Founder
Divi Murali Krishna Prasad
Key People
Satchandra Kiran Divi (CEO)
Founded
1990
Revenue
$1.2 billion (2022)
Subsidiaries
Divis Laboratories (USA) Inc, Divi’s Laboratories Europe AG, Divi’s Nutraceuticals
Standing tall since 1990, Divi’s Laboratories is India’s second pharma company by market capitalization touching nearly $17 billion in 2021. It is one of the leading pharmaceutical companies in the world that is engaged in manufacturing Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceuticals. The Hyderabad-based pharma company is also recognized as a Reliable Supplier of generic APIs and Custom manufacturers to Big Pharma.
The company has two subsidiary brands namely:
Divi’s Laboratories (USA) Inc -located in New Jersey, USA
Divi’s Laboratories Europe AG – Basel, Switzerland
Divi’s Laboratories has three manufacturing units located near Hyderabad and Visakhapatnam in India, and three R&D centers with more than 400 scientists and 42 patents across India. As the company is the world’s leading manufacturer of APIs, Intermediates, and Registered Starting Materials, it also provides high-quality goods with the greatest degree of compliance and virtue to more than 100 countries. Divi’s Laboratories was listed as a public limited business on the Indian stock exchange.
The manufacturing zones of Divi’s laboratories have been audited by authorities such as Regulatory Authorities, several Big Pharma/Multinational Companies, Statutory Authorities, and Global Environmental, Health, and Safety teams. On top of that, agencies such as USFDA, EU GMP (UK, Slovenia, German, and Irish authorities), HEALTH CANADA, TGA, ANVISA, COFEPRIS, PMDA, and MFDS keep have all visiting its advanced manufacturing plants in Hyderabad and Vizag for inspection.
One of the most recent achievements of Divi’s is the distinction of being one of the top three API manufacturers in the globe, as well as one of the top API firms in Hyderabad. Divi’s Lab claims to have more than 17,000 trained people who work tirelessly to make the company the leading pharma company in India.
Divi’s Laboratories – Industry details
According to experts, the global pharmaceuticals manufacturing industry is predicted to expand at a compound annual growth rate (CAGR) of 11.34% from 2021 to 2028. The Indian pharmaceutical sector is expected to be worth US$ 49 billion in FY22, representing a 9% increase over FY21.
The introduction of new technologies and efficient manufacturing types of equipment has transformed this industry massively following which, the industry is only expected to grow positively to newer heights. India is the largest contributor to exports, followed by North America, African countries, and Europe.
Divi’s Laboratories – Founder and Team
The founder of one of the leading APIs manufacturer companies, Divi’s Laboratories, is Dr. Divi Murali Krishna Prasad.
Divi Murali Krishna Prasad
Dr. Divi Murali K. Prasad was born in a small village in Andhra Pradesh. He was the youngest among his twelve other siblings.
Dr. Divi Murali is a graduate of the Manipal College of Pharmaceutical Sciences with a degree in Bachelor of Pharmacy. His career started by working at Warners Hindustan Company. While working at Warners, Dr. Divi Murali left for America with his family during 1976-77 in search of better opportunities. Dr. Divi Murali’s entrepreneurial journey began in 1984 after he came to India after working in key research and development positions at American companies such as Fike Chemical.
Upon returning to India, Dr. Divi Murali met Dr. Anji Reddy, the founder of Dr. Reddy’s Laboratories, with whom he bought a company called ‘Keminar’. Eventually, with the experience and knowledge, Dr. Divi Murali had gained, he finally founded his own company, Divi’s Laboratories in 1990.
Presently, Dr. Divi Murali Krishan Prasad is the Chairman and Managing Director of Divi’s Laboratories. He is also a member of the American Institute of Chemical Engineers, American Chemical Society, and American Cosmetic Society. He was listed as the 45th wealthiest man in India in 2013 as Forbes listing. Furthermore, he was featured in Hurun India Rich List 2021 with a net worth of ₹79,000 crores making him the 14th richest person in India.
Dr. Satchandra Kiran Divi
Commonly known as Kiran Divi is the Whole-time Director & Chief Executive Officer of Divi’s Laboratories. Dr. Kiran Divi is the son of Dr. Murali Divi. He is also the youngest billionaire in the Telugu States with a stake of 20.34% in Divi’s Labs. Dr. Kiran Divi holds a bachelor’s degree in Pharmacy from Mangalore University and a master’s degree from Jawaharlal Nehru Technological University. Along with this, Dr. Kiran Divi achieved a doctorate from the Gitam Institute of Technology and Management. He is married to Shakuntala Divi. The pharma company has been producing high-quality company strategies and plans under his guidance, guaranteeing alignment with both short and long-term objectives.
Nilima Prasad Divi
Nilima Prasad Divi is the Whole-Time Director (Commercial) of Divi’s Labs. She holds a master’s degree in International Finance from the University of Glasgow, UK. She oversees Material Sourcing & Procurement, Corporate Finance, and Investor Relations.
Ms, Nilima owns a stake of 20.34% in Divi’s Laboratories, which makes her a billionaire woman and also the richest woman in the Telugu States. Ms. Nilima also manages the company’s Material Sourcing & Procurement, Corporate Finance, and Investor Relations. Ms. Nilima developed substantial business acumen and knowledge with material need planning and finance before joining Divi’s.
Divi’s Laboratories – Startup Story
Divi’s Labs started as a Research & Development Centre as its core area in 1990. It grew and concentrated on inventing novel processes for the manufacturing of Active Pharmaceutical Ingredients (APIs) and Intermediates, as well as delivering comprehensive turnkey solutions and advising to the local pharmaceutical sector. Divi’s Laboratories’ brand name was changed from Divi’s Research Centre in 1994. Later after, in 1995, the business opened its first manufacturing facility in Choutuppal, Telangana. Its second production plant, located near Visakhapatnam, began operations in 2002.
On February 17, 2003, Divi’s Labs went public with an initial public offering (IPO). In 2007, the pharma company set up a Nutraceuticals facility at its Manufacturing Unit 2, near Vishakhapatnam. After a few years, the organization opened a research center in Hyderabad in 2010. Today, the company is a leader in producing one of the highest quality APIs and other drugs and medicines.
Divi’s Laboratories – Mission and Vision
The vision statement of Divi’s Laboratories is, “To create value for all stakeholders by manufacturing high-quality Generic APIs, Custom synthesis of APIs & Intermediates along with Nutraceutical Ingredients to the Global Pharmaceutical & Nutraceutical industry through sustainable leadership in chemistry.” The company aims to add some significance in the area of manufacturing through its core values and serving society in general.
Its mission is, “To be a responsible business, adding value through our core competency in the area of chemistry while adhering to our core values and serving the immediate community and at large through our diverse social initiatives that would establish a strong foundation for a better tomorrow for all stakeholders.”
Divi’s Laboratories consists of five core business values:
Financial Stability
Reliable Supply Partner
Trustworthy
Transparency
Complimentary
Divi’s Laboratories – Name, Tagline, Logo
The name of the company is after the founder Dr. Murali Divi’s family name, ‘Divi’.
The tagline of Divi’s Laboratories is, “Striving for leadership through chemistry”.
Divi’s Laboratories – Business Model
The business model of Divi’s Laboratories operates on a B2B model.
Its business mostly engages in export markets and features a diverse product portfolio that includes generics APIs and bespoke synthesis. The company includes World-class production facilities with a total capacity of 14000 m3, one of which is the world’s largest API manufacturing plant. It has three major manufacturing units near Hyderabad and Visakhapatnam. Two huge cGMP API manufacturing machines produce thousands of tonnes of APIs that are sold to over 100 countries.
With its motto, “Delivering a product with a value proposition, throughout the life-cycle of the product“, Divi’s Laboratories have about 400 best-in-class scientists working in their three R&D facilities across India. DRCs, Divi’s Labs Research Centres are located in Sanath Nagar, Hyderabad, while Process Development & Support Centres (PDSCs) are located at the production locations.
There are more than 2000 employees who are assigned to Divi’s Labs Quality Assurance and Quality Control. These employees are dedicated to upholding the highest quality standards in cGMP production through frequent assessments and ongoing development of the Quality Management System. As mentioned earlier, all the manufacturing facilities are fully inspected regularly by top health agencies such as the FDA, EU GMP, HEALTH CANADA, TGA, ANVISA, COFEPRIS, PMDA, and MFDS.
Generic APIs products
The pharma companyis a global pioneer in High Volume Generic APIs. The product list contains a highly selected 30 APIs that are commercially made in batches of tens to hundreds to thousands of Tonnes per year, thus making it the world’s largest API manufacturer.
To name a few generic APIs products, these are Bupropion HCl, Diltiazem HCl, Gabapentin, Levetiracetam, Capecitabine, Nabumetone, Pregabalin, Quetiapine Fumarate, Valsartan, Triprolidine HCl, and many more. Some of these products are regulated by other countries like Australia, Singapore, Saudi, China, Thailand, Korea, EU Countries, and Taiwan among others.
The company is currently developing new eight products in the therapeutic categories such as – anti-diabetic, anti-viral, anti-hypertension, anti-coagulant, etc.
Custom Synthesis
Divi’s Laboratories is also engaged in the business of manufacturing customized synthesis, which means it offers its manufacturing services on a contract basis for many global pharma companies. It has established relationships with 6 of the top 10 Big Pharma.
Nutraceuticals
Located at its Unit II manufacturing location, the Nutraceutical Facility by Divi’s is an integrated facility for the synthesis of active ingredients as well as final forms of carotenoids. It is one of the world’s leading producers of Carotenoids. The facility contains a full-service R&D, application testing, and support center. Divi’s Laboratories’ nutraceutical product line includes a complete spectrum of carotenoids such as Beta Carotene, Astaxanthin, Lycopene, Canthaxanthin, and Canthaxanthin, as well as additional completed forms such as Lutein and Vitamins, these include A, D3, D2, E Acetate, and A Palmitate. This high-quality carotenoid and vitamin components by Divi’s are used by many food & beverage, nutritional supplement, pet food, and feed sectors.
Since its inception, Divi’s has concentrated on various corporate social responsibility initiatives, affecting the lives of thousands of people living in and around Andhra Pradesh and Telangana. Its CSR initiatives include promoting education, empowering women, rural development, preventive health care, safe drinking water, animal welfare, and raising the living standards of community members.
So far, Divi’s Laboratories have empowered more than 22,000 children by building around 206 schools and providing around 92 safe drinking water to more than 2,41,000 people in villages. Alongside, the company has executed more than 1,36,000 plantation drives in 35 villages, and more.
The company has distributed Study material to 10th-grade students across the government schools in Andhra Pradesh, distributed Horlicks Sachets to 180 schools, and donated dual desk benches to Government schools. It has also dedicated its efforts to improving the lives of many villagers in Panthangi village in Telangana and Chippada village in Andhra Pradesh through its Model Village Project.
Divi’s Laboratories has also dedicated itself to a sustainable environment by launching various sustainable initiatives like Water Management (installed new Sewage Treatment Plants (STPs) at manufacturing sites aided in the saving of 1,22,400 M3 of water) Energy Management (Installed advanced and energy efficient equipment – 1,08,79,000 KWH), and Waste Management (solvent recovery stations were established to recover and reuse solvents)
Their CSR activities don’t end there. Besides, over 33,550 EHS training sessions were conducted, with 3,30,900 participants.
Divi’s Laboratories Covid-19 Response
In response to the pandemic, the company has been very quick to implement tight measures at its sites. Divi’s has been checking all of its business processes and production schedules, prioritizing activities of significance such as making sure appropriate behavior of its employees following all safety and sanitation protocols and ensuring its supply chain’s engagement with vendors and customers. Even though there were certain pitfalls, in the beginning, it has been able to sustain its business operations and assure an ongoing supply of active pharmaceutical ingredients to clients for the manufacture of important medications. The pharma company has also begun to vaccinate its employees and their dependents.
Divi’s Laboratories – Revenue Model & Growth
For Fiscal Year 2021-22, Divi’s Laboratories has been able to achieve another year of decent business growth and profitability. As the company is primarily engaged in the export market, the exports accounted for 90% of total sales income, and 77% of commerce was conducted in cosmopolitan markets such as Europe and America. The Rest of the World accounted for 4.0%, Asia for 9.2%, and India accounted for 10.0%.
The company made a revenue of $1.2 billion in 2022. It claims to have a revenue growth of 31%.
Revenue Distribution of Divi’s Laboratories
Divi’s Laboratories – Shareholdings
Divi’s Laboratories is a publicly listed company with its IPO in 2003. Its ISIN code is INE361B01024. The company has been funded by many fund managers. Some of the important ones have been highlighted in the following list:
Fund Name
Fund Manager
Shares in %
SBI Equity Hybrid Fund-Reg(G)
R. Srinivasan
2.89
Axis Long Term Equity Fund-Reg(G) Jinesh Gopani
4.60
SBI BlueChip Fund-Reg(G)
Sohini Andani
2.92
SBI Nifty 50 ETF
Raviprakash Sharma
0.65
Axis Bluechip Fund-Reg(G)
Shreyash Devalkar
1.90
UTI Flexi Cap Fund-Reg(G)
Ajay Tyagi
1.39
Nippon India Pharma Fund(G)
Sailesh Raj Bhan
7.47
UTI Nifty 50 ETF
Sharwan Kumar Goyal
0.65
Axis Growth Opp Fund-Reg(G)
Jinesh Gopani
2.25
Aditya Birla SL Equity Hybrid 95 Fund(G)
Satyabrata Mohanty
1.70
Aditya Birla SL Pure Value Fund(G)
Milind Bafna
3.19
SBI Healthcare Opp Fund-Reg(G)
Tanmaya Desai
6.89
UTI Mastershare-Reg(G)
Swati Kulkarni
1.12
SBI Magnum Equity ESG Fund-Reg(G)
Rohit Shimpi
2.12
Sundaram Large and Mid Cap Fund(G)
Ravi Gopalakrishnan
1.43
Aditya Birla SL Pharma & Healthcare Fund-Reg(G)
Dhaval Shah
6.62
Edelweiss Nifty 100 Quality 30 Index Fund-Reg(G)
Bhavesh Jain
3.04
Motilal Oswal S&P BSE Healthcare ETF
Swapnil P Mayekar
8.18
Axis NIFTY Healthcare ETF
Jinesh Gopani
10.58
Aditya Birla SL Nifty Healthcare ETF
Lovelish Solanki
10.59
Divi’s Laboratories – Awards and Achievements
Divi’s Laboratories has been a continuous recipient of many prestigious awards for its manufacturing, CSR, and sustainability activities. Here’s a list of awards achieved by the company in recent years:
2022
Divi’s received the EHS excellence Award by CII South Region
2021
Lifetime Achievement Award by ICON SWM
Lifetime Achievement Award for significant contribution to the circular economy and waste management by International Society of Waste Management, Air & Water (ISWMAW)
Divi’s received the CII-SR EHS Excellence Award 2020 – “4 Star Rating” for commitment to EHS practices
It has received India’s most prestigious Safety Award ‘Suraksha Puraskar Award for the year 2021 from theNational Safety Council of India (NSCI)
2020
Achieved the Prashansa Patra – NSCI Safety Awards -2020 from the National Safety Council of India (NSCI)
2019
Divi’s was recognized as the Best Partner – Smart Village Smart Ward by Andhra Pradesh State Government
CII EHS Excellence Awards 2019 – 3 star rating by the Confederation of Indian Industry (CII)
Divi’s Labs was recognized as the 2019 HURUN Self-made Philanthropist of the Year as per Hurun Report
2018
Divi’s Labs achieved IconSWM (International Conference on Sustainable Waste Management) by the International Society of Waste Management, Air & Water
Achieved the May Day award for Best Management Department of Labour, Government of Andhra Pradesh
The company aims to expand its capacity in producing more specialized APIs to the changing marketing conditions. As the leading pharma company for manufacturing customized APIs, it further wants to expand by seeking to hit a market size of $20 billion in molecules going off-patent during FY23–25.
FAQs
Who owns Divi Labs?
Divi Murali Krishna Prasad is the owner of Divi Labs.
What is the full form of API in pharma?
In pharma, API stands for Active Pharmaceutical Ingredient.
Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Giani.
Who doesn’t love the sweetened frozen food known as Ice cream? Be kids or adults, ice cream is consumed as a snack or dessert by many of us. Whether you are in the mood of having a mini celebration with your friends or even want to treat someone just to lighten up their day, ice cream comes to our mind right away.
The origins of ice cream started around 500 BCE. In South Asia, the concept of ice cream began when the Mughals used to get ice from the Hindu Kush to its capital Delhi and used it in fruit sorbets.
Giani, the ice cream brand we all are familiar with, is one of the oldest ice cream brands in India. Established as a small ice cream shop in 1956 by Giani Gurcharan Singh, Giani ice cream made it big and has over 200 stores across India today.
Here’s the story of how Giani kept its legacy over all these years. Know everything about Giani’s founder, its mission and vision, its business and revenue model, and so on.
Giani Ice Cream, founded in 1956 in Fatehpuri, Delhi, is a company that manufactures and sells ice cream, faluda kulfi, Italian gelato, sorbet, and snacks. Its cutting-edge infrastructure, which spans 15,000 square feet in Manesar and Delhi, is divided into a variety of departments such as processing, quality testing, cold storage, and packing.
Giani’s delicious vegetarian ice cream and snacks are enjoyed by children, teenagers, and adults alike. Their production facility has a low-temperature hardening chamber, a continuous freezer, and filling stations.
The company can undertake pasteurization, homogenization, hardening, aging the mix, freezing, and packing at its structures under the charge of an efficient team comprised of food specialists, nutritionists, quality controllers, sales professionals, and administrative staff.
Giani’s products are made with high-quality milk, cream, chocolate, fruits, and other natural ingredients to make for excellent nutritional value and low-fat content frozen desserts.
The brand is prevalent throughout India, with 40 franchisee locations in Delhi/NCR alone.
Giani also offers a personalized meal for all events to commemorate a particular occasion such as Anniversaries, Marriages, or any parties. It provides outdoor catering at a variety of places around Delhi and the NCR region.
Giani – Industry details
The Indian ice cream industry is expected to increase at a CAGR of 17.3 percent between 2021 and 2026. The demand for increased need for different types of ice cream flavors is what pushes the industry to newer heights. As per reports, the global ice cream market was valued at $79 billion in 2021. Furthermore, the global ice cream industry is projected to grow at a CAGR of 4.2% from 2022 to 2030.
Giani – Founder and Team
Giani is founded by Giani Gurcharan Singh in 1956.
Giani Gurcharan Singh
Giani Gurcharan Singh is the creator of the Giani ice cream shop brand. He moved to Delhi from Faislabad, Pakistan, and settled as a refugee in Delhi’s Fatehpuri, Chandni Chowk. Giani Gurcharan Singh opened the first store under the name ‘Giani Di Hatti. The business was then called Giani and slowly started developing additional branches in Delhi and other regions of North India. It was believed that Giani Gurcharan Singh had a sweet shop in Pakistan before moving to India. He even used to make all the desserts by his hand and used high-quality ingredients.
Giani – Startup Story
The story begins in 1956 in Giani-di-Hatti, a landmark of ancient Delhi tucked among the Fatehpuri and Chandni Chowk bazaars. Giani Gurcharan Singh, a traditional sweetmeat maker from Layallpur (Faislabad), Pakistan, started his business after relocating to Delhi.
By making all the desserts by his hands, Giani Gurcharan Singh began serving his famed rabri-faluda and mango shakes, which he produced with great care and passion using only the highest quality ingredients. This struck a chord with the discriminating citizens of the walled city, and Giani became popular in the city.
In 1970, the company was split into two parts: Gurcharan Sons and Giani Ice Cream. In the same year, Giani Gurcharan Singh took over Giani Ice Cream and requested his eldest son Shri Gurbachan Singh, who was still an undergraduate at the time, to join the company and add ice cream flavors to the company’s traditional sweets.
The success of the company was due to Giani Gurcharan Singh’s commercial acumen, as well as his ability to make ice cream with his hands. It was an age when politicians and celebrities like Raj Kapoor and Mohammad Rafi would come to savour the food and take up the ambiance.
Giani Gurcharan Singh’s three children chose to split up in 2007. Shri Gurbachan Singh, the eldest of the brothers, and his son Shri Taranjit Singh opted to continue the family heritage and kept Giani Ice Cream to develop the chain of franchise ice cream restaurants across NCR under the original brand.
Giani Ice Cream has successfully spanned age ranges and found universal appeal among ice cream enthusiasts with over fifty locations.
It combines the memories of Chandni Chowk’s famous and classic rabri-faluda, chilled mango shakes with the current desire for chocolate whiskey ice cream. It also has a range of sundaes, mousses, and shakes, as well as gelatos, frozen yogurts, and health-conscious inventions like jamun sorbet.
Giani – Name, Tagline, Logo
Giani – Business & Revenue Model
Giani operates as a franchisee-based business model. It is present in over 200 stores across states like Uttar Pradesh, Chandigarh, Punjab, Rajasthan, Haryana, Himachal Pradesh, Odisha, West Bengal, Maharashtra, Telangana, etc.
The company is engaged in offering a wide variety of ice cream, faldua kulfi, Italian gelato, sorbet, and snacks. All of the products of Giani are manufactured under strict quality standards to provide excellent nutritional value and minimal fat content. To retain taste and freshness, ice cream is kept at the proper temperature.
The company’s business operations also offer catering services for different occasions such as marriages, and birthday parties. Giani is reported to have made a revenue of Rs 18 crores during 2019-2020.
During the pandemic time, the company made the best use of time to rethink and work on its packaging and menu. It introduced sealed glass jar packaging and expanded its menu to provide clients with additional options.
Giani made a good amount of sales during Covid-19 as online orders increased because of the digital payment mode and contactless deliveries.
Giani already has made its benchmark by having over 200 stores across India. Its objective over the next few years is to outperform all competitors as India’s leading player as an ice cream brand. It also intends to expand its international reach and target the global market in the coming years.
FAQs
Who is the CEO of Giani Ice-creams?
Gurbachan Singh is the current CEO of Giani Ice-creams.
Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Cadila Healthcare Limited.
To begin, the pharmaceutical industry has shown immense growth over the years. Every pharma product goes through a series of stringent research, innovation, and regulation to deliver good quality drugs and medicines, after all, it is a matter of health.
One cannot even imagine a life without medicines and drugs. Today, we have so many medicines for flu and fever and other key discoveries related to prolonged illnesses as well.
Previously known as Cadila Healthcare Limited, Zydus Lifesciences Limited, an Indian multinational pharma company is primarily engaged in the manufacture of generic drugs. Founded in 1952 by Ramanbhai Patel, Zydus Lifesciences Limited has its corporate office in Ahmedabad (Gujarat), India.
Zydus Lifesciences is thoroughly engaged in producing formulations for active pharmaceutical ingredients, animal healthcare products, and wellness products. Furthermore, it creates and produces a wide variety of medications, diagnostics, herbal remedies, cosmetics items, and other over-the-counter (OTC) goods.
It is a leading Indian pharmaceutical business and a fully integrated, international healthcare provider. It has excellent capabilities across the whole pharmaceutical value chain and extensive domain understanding in the field of healthcare.
Zydus Lifesciences has its headquarters in Ahmedabad, India. It has the fourth-place position in the country’s pharmaceutical market, with production and research facilities dispersed over five states: Gujarat, Maharashtra, Goa, Himachal Pradesh, and Sikkim. Globally, the group is well-represented in the highly visible markets of Latin America and South Africa as well as the regulated markets of the US and Europe (France and Spain). It is also well-established in 25 other developing markets throughout the world.
Zydus is a pharmaceutical business focused on research, along with 1300 researchers operating across 19 facilities on its innovation program, which is developing distinctive medications for the future. NCEs, vaccines, biosimilars, and specialized technologies are just a few of the ideas and concepts the group is studying while also constantly inventing.
Zydus Lifesciences has four major subsidiaries, these are:
Zydus Wellness Limited (ZWL) – The company re-launched the Complan brand with improved taste and packaging design
Lipaglyn Saroglitazar – A new drug in treating Diabetic Dyslipidemia
Exemptia Adalimumab – It is ananti-inflammatory drug
ZyCoV-D – The Drugs Controller General of India (DCGI), Government of India, granted the company authorization to undertake human trials of the developing COVID-19 vaccine dubbed ZyCoV-D in 2020.
Zydus Lifesciences’ CSR & EHS initiatives
The company’s aims and business operations include a commitment to environmental conservation, employee health, and safety. It has a dedicated Environment, Health, and Safety (EHS) cell that works with all stakeholders across functions to create a distinct EHS culture to achieve environmental, health, and safety excellence across all units.
Zydus Shrishti, the company’s CSR initiative, focuses on health, education, and research. The Zydus Foundation has established the Zydus Medical College and Hospital in Dahod. The hospital provides free care for patients, including OPD, hospitalization, all investigations, operations, anesthesia, oral drugs, injectables, and meals.
It has also set up a medical college in Dahod, which is a self-financed brownfield medical college project established under the Government of Gujarat’s Public Private Partnership (PPP) model.
Zydus has conducted over 3000 awareness sessions on the prevention of various disease conditions.
Zydus Lifesciences Limited – Industry Details
The pharmaceutical business is massive, with a global market of more than US$ 1.4 trillion. Moreover, COVID-19 increased worldwide drug consumption, owing to fast immunization and the development of novel treatment options. Global COVID-19 investment is estimated to approach $80 billion in 2021, with total spending exceeding $251 billion through 2026.
Nevertheless, India is a prominent and expanding player in the global medicines market. It is no surprise that India is the world’s largest provider of generic pharmaceuticals, accounting for 20% of global supply by volume and fulfilling over 60% of global immunization demand.
Zydus Lifesciences Limited – Founder and Team
Zydus Lifesciences Limited was founded by Indian chemist, Ramanbhai B. Patel in 1952.
Ramanbhai B. Patel
Ramanbhai Patel was born in South Gujarat in Kathor on 19 August 1925. Before working as an instructor there, he was a student of chemistry at Gujarat University’s L.M. College of Pharmacy. He founded Cadila Laboratories with his school friend Indravadan Modi in 1951. However, due to some disagreements, the business split in two in 1995; Raman Patel established Cadila Healthcare, and Modi established Cadila Pharmaceuticals. The 2019 Gandhi Mandela Peace Award was hosted by Ramanbhai Patel. Ramanbhai Patel passed away on 19 September 2001 in Mumbai, India.
Pankaj R. Patel
Pankaj Ramanbhai Patel is a multimillionaire businessman. He was born in 1953 and is the Chairman of Cadila Healthcare, now known as Zydus Lifesciences. He has a Bachelor of Arts in Science and Law from the University of Mumbai, and a Bachelor of Pharmacy and Master of Pharmacy degrees from Gujarat University. Pankaj Patel joined Cadila Healthcare, which was established by his father, Ramanbhai Patel in 1952 to produce vitamins, after receiving his degree.
Pankaj Patel serves as the chairman of the boards of governors of the Indian Institute of Science Education and Research in Kolkata and the Indian Institute of Technology in Bhubaneswar. He is also a member of the boards of governors and the chairman of the finance committee of the Indian Institute of Management in Ahmedabad, the chairman of IIM Udaipur, the chairman of the school of life sciences at Ahmedabad University, and the board of management of the Ahmedabad University.
In honor of the expansion of Cadila under his direction, Pankaj Patel was named the “Best Pharma Man of the Year of 2003” by the Foundation of Indian Industry and Economists. Pankaj Patel is married to Priti Patel and has two children.
Zydus Lifesciences Limited – Startup Story
The story begins when Ramanbhai Patel and his business partner Indravadan Modi established Cadila in 1952. Over the subsequent forty years, it developed into a well-known pharmaceutical corporation.
In those years, Isopar, a combination of the anti-tuberculosis medications isoniazid and para-aminosalicylic acid, was produced in 1957, and Neuroxin-12, a single-vial mixture of vitamins B1, B6, and B12, was produced in 1959.
Things got changed when the Modi and Patel families separated in 1995. The Modi family’s portion was transferred to a new business called Cadila Pharmaceuticals Ltd., while Cadila Healthcare Ltd. became the holding company for the Patel family. In 2000, Cadila Healthcare under the stock number 532321 had its first public offering on the Bombay Stock Exchange.
Under the trade name Exemptia, Zydus Lifesciences introduced the first adalimumab biosimilar in 2014 at a price that was one-fifth that of the original. Saroglitazar, a medicine based on research, has also been made available by the company under the trade name “Lipaglyn” for the treatment of diabetic dyslipidemia. Zydus introduced SoviHep, the first sofosbuvir brand, to India in 2015.
2019 saw the recall of injectable ketorolac tromethamine produced by Zydus (Cadila Healthcare) owing to microbial development.
Zydus Lifesciences Limited replaces Cadila Healthcare Limited as the company name in 2022.
Zydus Lifesciences Limited – Mission and Vision
The mission statement of Zydus is, “To unlock new possibilities in life sciences through quality healthcare solutions that impact lives.”
Zydus’s vision reads, “To be a global life sciences company transforming lives through pathbreaking discoveries.”
The company aims to give people the independence they need to lead healthier, and more contented lives.
Zydus Lifesciences Limited – Name, Tagline, Logo
Before Zydus Lifesciences, the company was popularly known as Cadila Healthcare Limited. The tagline of Zydus Lifesciences is, “Dedicated to Life”
Its new logo depicts a stylized representation of two hearts with the word “Us” in the middle. Zydus’s logo colors are vivid and deeply symbolic highlighting the fact that everything the company does is for them which is “Us”, which includes the company’s diverse group of stakeholders, including staff members, patients, carers, partners, and customers.
The teal color in the logo expresses the company’s dynamism and purple symbolizes its purposefulness and dedication.
Zydus Lifesciences Limited – Business Model
As mentioned earlier, Zydus is mainly involved in the manufacturing of generic drugs, APIs, Animal healthcare products, and other OTC goods. The company has a global manufacturing footprint of 35 facilities that adhere to strong regulatory compliance requirements and have the capacity to manufacture multiple dosage forms at scale, allowing it to provide clients globally with cost-effective and high-quality pharmaceutical goods. About 7-8% of its annual revenues are invested in research and development.
Here’s taking a look at Zydus’s main business operations:
Zydus Research Centre (ZRC) is the company’s specialized unit in charge of driving its NCE research efforts. Cardiometabolic illnesses, inflammation, fibrosis, and infectious diseases are among ZRC’s NCE research priorities.
The Company’s vaccine development projects are housed in the Vaccines Technology Centre (VTC) in Ahmedabad. VTC has been working on vaccines for basic vaccination programs such as Diphtheria, Pertussis, Tetanus, Haemophilus Influenzae type B, Hepatitis B, Measles, Mumps, Rubella, Varicella, Influenza, and Typhoid fever, as well as new vaccines such as Human Papilloma Virus, Leishmaniasis, Malaria, Haemorrhagic Congo Fever, Ebola, and Japanese Encephalitis.
Specialty and Complex Generics. The Company’s Specialty portfolio is focused on offering value-added therapies that meet unmet requirements while also providing patients and providers with a viable economic opportunity.
The company has one of the most complete and diversified biological product portfolios. The portfolio includes therapeutic fields like oncology, autoimmune illness, nephrology, ophthalmology, and other fields, including rheumatology, inflammation, hepatology, infectious illness, etc.
The group’s generic pharmaceutical development R&D operations are carried out in three Pharmaceutical Technology Centres (PTC) in Ahmedabad, India. These Centers provide formulations for worldwide markets, with a focus on specialty dosage forms and the development of skills on multiple technological platforms.
Zydus’s India Business
The company’s domestic’s business is divided into three major business segments; specialty business, chronic business, and mass business. It was the fastest growing company in India in the oncology sector while maintaining a leadership position in the super specialty of nephrology. To prevent and treat a variety of diseases in the fields of oncology, hepatology, nephrology, rheumatology, ophthalmology, and bone health, Zydus Biologics, a super-specialty centric business entity of Zydus Lifesciences Ltd., manufactures and commercializes both small molecule, biological drugs, and vaccines. It has launched around 37 new products including line extensions, out of which 13 were first in the domestic market.
Domestic sales increased by 7% to Rs 19,788 million, with a 160% increase in net profit to Rs 3,089 million. (FY2021-2022)
Zydus’s USA Business
Zydus Lifesciences has been ranked 5th among US generic companies based on prescriptions. The company’s business involved the launch of 14 products during 2021-2022. Despite growing competition and pricing pressure, the company tends to gain total volume and maintained a top three ranking in around 60% of product families. In terms of volume, the company led in around 20% of the product groups. Sales made in the USA were reported to be Rs 58,138 million.
Zydus’s Asia, Africa, and Latin America Business
With 30 products classified as leaders in their respective molecular categories, the company reclaimed first place in Sri Lanka with a 7.4% market share. Zydus’s international business sales increased by 17% to Rs 11,921 million.
Zydus Lifesciences Limited – Revenue Model
The total revenue made by Zydus Lifesciences is reported to be Rs 15,139 crores. It claims that its total income from operations grew by 6% to Rs 152.7 crores from Rs 144 crores last year (2020-2021). There was a 21% Y-o-Y increase in the branded business (excluding sales of COVID-related products, the generics portfolio, and sold brands). Twelve of the company’s products are among India’s top 300 pharmaceutical brands. During 2021-2022, eight brands had sales above Rs 100 crores, 22 brands had sales between Rs 50 and Rs 100 crores, and 36 brands had sales between Rs 25 and Rs 50 crores.
Zydus Lifesciences Limited – Funding and Investors
Zydus Lifesciences Ltd. has three joint ventures. Some of these are;
Zydus Takeda Healthcare Pvt. Ltd. – It is a 50:50 joint venture between the Company and Takeda Pharmaceuticals Co. Ltd., (Japan)
Zydus Hospira Oncology Pvt. Ltd – It is a 50:50 contract manufacturing joint venture between Zydus and Hospira Inc., USA (now part of Pfizer group)
Bayer Zydus Pharma Pvt. Ltd. – Bayer (South East Asia) Pte. Ltd. (wholly owned subsidiary of Bayer AG, Germany) and Zydus Lifesciences Limited have a 75:25 marketing joint venture.
Zydus Lifesciences Limited – Mergers and Acquisitions
Zydus Lifesciences has raised a total of $7 million in investment. It was funded by Baring Private Equity India in a Post-IPO Equity round.
Zydus Lifesciences Limited – Mergers and Acquisitions
Till now, Zydus has purchased three businesses. Windlass Biotech was their most recent purchase as of August 13, 2018. For Rs 160 crores, they bought Windlass Biotech. Windlass Biotech is Gurgaon-based healthcare that engages in pharmaceutical drug development and contract research services. Here is the list of acquisitions made by Zydus:
Date
Acquiree name
Amount
August 13, 2018
Windlass Biotech
Rs 160 crores
January 19, 2017
Sentynl Therapeutics, Inc.
–
December 22, 2011
Biochem Pharmaceuticals
–
Zydus Lifesciences Limited – Advertisements and Social Media Campaigns
Recently, Zydus Lifesciences re-launched the popular energy drink of children ‘Complan’ with improved taste. It was accompanied by the tagline “Ummeedo se aage badhne ka plan” campaign, which communicates the crucial advantages of the brand. The advertisement focuses that if children consume Complan it will not only improve their growth but also their memory and attention.
Zydus Lifesciences Limited – Awards and Achievements
The list of awards and achievements won by Zydus Lifesciences are;
Zydus received the IDMA Aptar innovation of the year award and Corporate citizen award (2022)
Pharma Company Of The Year Award by ETHealthworld India Pharmaworld Awards 2022
Zydus achieved the HR Asia award in the category of Best Companies to work in Asia 2021 in the India region.
Zydus was declared the most Innovative Pharmaceutical Company by Thomson Reuters.
Zydus received the 7th India Pharma and India Medical Device award by the Government of India (2021-2022)
Zydus was recognized for Excellence In CSR at ETHealthworld India Pharmaworld Awards 2022.
Zydus Lifesciences was recognized as India’s Best Workplace in Biotechnology and Pharmaceuticals by Great place to work 2022.
Zydus Lifesciences Limited – Competitors
The list of top competitors of Zydus Lifesciences is:
Zydus Lifesciences Ltd. recently announced the acquisition of up to an 11.86% stake in AMP Energy Green Nine. The company is also planning to launch Lenalidomide capsules, which is a cancer treatment medication that works in slowing or preventing cancer cell proliferation in the USA market.
FAQs
Who is the CEO of Zydus?
Tarun G Arora is the CEO of Zydus.
Is Zydus a public company?
Yes, Zydus is a public company.
Where is the headquarter of Zydus Lifesciences?
The headquarter of Zydus Lifesciences is in Ahemdabad.
What is the rank of Zydus in India?
In Ind, Zydus ranks as the 4th biggest pharma company.
Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Sun Pharma.
It was in the mid-1800s when pharma industries started by distributing botanical drugs such as morphine. Gradually, with applied research studies, the industry started picking up pace, which resulted in the development of new drugs.
The post-world wars gave birth to a wide variety of new antibacterial drugs. Ever since pharmaceutical manufacturing companies have been significant in creating potential drugs, that many of us are familiar with in our day-to-day lives.
In the 1980s, a lot of pharmaceutical companies started to hit up the market, and one of them was Sun Pharma. With their continuous efforts and innovations,Sun Pharmabecame the largest pharmaceutical company in India and the fourth-largest speciality generic pharmaceutical company in the world.
This article covers all the suitable information related to Sun Pharma, like its success story, its founders, its key products and services, its business and revenue model, and more.
Sun Pharma, founded in 1983, is a global pharmaceutical firm that develops and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in over 100 countries worldwide with around 40 manufacturing facilities. Its R&D centres throughout the world, as well as a multicultural staff of over 50 nationalities. Countries like Brazil, Mexico, Russia, Romania, and South Africa are some of its key emerging markets. The company likes to promote excellence via strategic innovation, which is supported by strong R&D capabilities that include about 2,000 scientists and R&D spending of more than 7-8% of annual revenues.
Absorica, Acamprosate Calcium, Alendronate Sodium, Amifostine trihydrate, Budesonide, and Carvedilol are among its API products. Psychiatry, anti-infectives, neurology, cardiology, orthopaedic, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dentistry, and nutrition are among the therapeutic categories served by Sun Pharma. The company claims to have more than 37,000 people employed across its global offices.
Sun Pharma consists of having a diversified speciality and generics portfolio that further consists of nearly 2000 high-quality compounds, which is available in a variety of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids.
Sun Pharma was placed on the stock exchange in 1994, with an issuance that was 55 times oversubscribed. The original family still owns the bulk of the corporation.
Sun Pharma – Industry
One of the biggest industries in the world is the pharmaceutical industry. Moreover, as per records, the Indian Pharmaceutical industry ranks third in the world in terms of pharmaceutical production by volume.
The pharma market has seen tremendous growth over the past few years, especially after the pandemic. The total revenue of the global pharmaceutical market was valued at $1.27 trillion in 2020.
Dilip Shanghvi is the founder and MD of Sun Pharmaceuticals Industries Ltd. He was born in the Indian state of Gujarat to Shantilal Shanghvi and Kumud Shanghvi in the tiny village of Amreli. Dilip Shanghvi’s career took a turn when he began by assisting his father at his business, a wholesale dealership of pharmaceuticals, primarily generic drugs in Kolkata. But later, he considered producing his pharmaceuticals rather than selling those manufactured by others. Today, he is one of the country’s richest people with a net worth of $14.3 billion. In 2016, the Indian government bestowed upon him the civilian honor of Padma Shri. After a year, India Today magazine rated him eighth on its list of the country’s most powerful persons.
Dilip Shanghvi was nominated to the Reserve Bank of India’s 21-member central board committee in January 2018. He is also the head of the IIT Bombay board of governors. There’s a book on him, which is the first and only biography of Dilip Shanghvi, ‘The Reluctant Billionaire’ written by journalist Soma Das. The book was nominated for Tata Literature Award in the Best Business Book category in 2019. Dilip’s wife’s name is Vibha Shanghvi. The couple has two children, one daughter, and one son.
Israel Makov
Israel Makov was the Non-Executive Chairman of the Company. He recently retired from the company in August 2022. Before becoming a part of Sun Pharma, Israel Makov served as the President & CEO of Teva Pharmaceutical Industries Ltd from 2002 to 2007. He had directed a variety of enterprises in diverse areas before joining Teva. Among them was Interpharm, his first biotech firm, which he started and later took public in the United States.
Israel graduated from the Hebrew University in Jerusalem with a B.Sc. in Agriculture and an M.Sc. in Economics. He is a member of the Weizmann Institute of Science’s Executive Board and Management Committee, the Technion’s Board of Governors, and a Director of Yeda Research and Development Company Ltd. Israel Makov is also the Chairman of Israel’s leading theatre, the Gesher Theatre.
Under Israel’s leadership, the company transformed from a $1.7 billion organization operating in India and USA to the world’s fourth-largest specialty generic pharmaceutical company operating in more than 100 markets.
Sun Pharma – Startup Story
The startup story of Sun Pharma started in Vapi, Gujarat, which is a few hours’ drive from Mumbai. Dilip Shanghvi set up his first manufacturing plant there with a capital of Rs 10,000. In the initial days, the pharma company manufactured only psychiatry drugs but it soon scaled up its business. By 1997, the company’s business was a hit and was able to make its first acquisition by acquiring Caraco Pharma, an American company.
At present, Sun Pharma is the market leader in fields like diabetology, cardiology, urology, gastroenterology, ortho, dermatology, vitamins, minerals, and nutrients, with nine other distinct specialties of specialists.
Sun Pharma – Mission and Vision
Sun Pharma’s vision is, “Reaching People And Touching Lives Globally As A Leading Provider Of Valued Medicines”
The firm wants to offer medicines that are of prime quality and affordable to most people.
The company follows its idealogy based on five core values:
Reliability
Trust
Quality
Innovation
Consistency
Sun Pharma – Name, Tagline, and Logo
Sun Pharma Logo
The name Sun Pharma is based on the idealogy of the sun.
The tagline of Sun Pharma reads, “Science is at the heart of Sun Pharma” The logo of the company is a symbol that is similar to the shape of the sun in bold orange and light orange colour combinations.
Sun Pharma – Business Model
Sun Pharma operates its business by manufacturing and selling pharmaceutical formulations and active pharmaceutical ingredients (APIs).
Sun Pharma produces an extensive variety of therapeutic segments, specialty medicines, generic medications, and over-the-counter (OTC)/consumer healthcare products with its brand names like Faringosept for sore throat treatment, Revital (multivitamins), Volini for topical analgesics. It further includes other categories of brands such as Coldact & Flustat, Brustan, Painamol & Paduden, Gestid, Aspenter, Aspacardin, Chericof, and Nudrate & Fortifikat.
Sun Pharma’s business operations also involve a wide range of Anti Retro Viral Medications (ARV), which are all qualified by WHO. The supplies ARVs to diverse National AIDS treatment programs in Africa. The company wants to contribute significantly to fighting HIV/AIDS by producing first-line and second-line Highly Active Antiretroviral Therapy (HAART). Its business operations are present in almost 100 countries.
Sun Pharma CSR Activities
Sun Pharma also focuses on serving and helping society. There are a lot of underprivileged communities in India, and Sun Pharma with its CSR activities aims to serve the community in three primary areas: health, education, safe drinking water, and sanitation.
The CST mission of Sun Pharma is, “To leverage our people, expertise, and networks to address the needs of the communities that we serve and thereby catalyze overall development.”
Sun Pharma has the following CSR projects:
Malaria Elimination Demonstration Project (MEDP)
A partnership between the Indian Council of Medical Research (ICMR), the Government of Madhya Pradesh (GoMP), and the Foundation for Disease Elimination and Control of India (FDEC India) is a non-profit enterprise with a primary focus on reducing malaria cases in over 200 villages of the Mandla district.
Mobile Healthcare Units (MHUs)
MHUs deliver primary healthcare services to more than 650,000 people who live near Sun Pharma’s manufacturing sites and other establishments. It offers services like health-check ups and free medicines.
Model School Development
This project is implemented to empower students coming from rural areas to give them the basic right to education and other development opportunities.
Safe Drinking Water and Sanitation
This project by Sun Pharma aims to provide access to hygienic and clean drinking water and good-quality washrooms and toilets in various regions in villages.
Sun Pharma Science Foundation
The Sun Pharma Science Foundation is a recognized non-profit organization under the Societies Act. This foundation gives motivation and encouragement to those who excel in the medical and pharmaceuticals line.
Environmental, Health & Safety (EHS) programs
The program of EHS by Sun Pharma aims an establishment of a safe and healthy workplace as well as a clean environment for all workers and the communities it serves.
Sun Pharms CSR
Sun Pharma’s Covid-19 initiatives
The company was deeply engaged in providing Covid-19-specific medicines to help curb the virus and the community in general. Some of the initiatives launched by Sun Pharma are:
‘Sunkalp’, is a special initiative by Sun Pharma for the welfare of doctors, their families, and the community.
Teamed up with MSD, popularly known as Merck in the United States and Canada. MSD gave special rights to Sun Pharma to manufacture, market, and distribute Molnupiravir in India.
Sun Pharma donated a sum of Rs 250 million of Hydroxychloroquine (HCQS), Azithromycin, other related drugs, and hand sanitizers in India. It has also made other donations related to Covid-19 medicines and PPEs within international boundaries.
Set up manufacturing units just to produce Covid-19-specific medicines such as Vecuronium (anaesthesia), Midazolam (anxiety), Ivermectin (antiviral), Azithromycin (antibiotic), and HCQS.
Sun Pharma launched FluGuard (Favipiravir 200 mg) in 2020. The tablet is set at an economical price of Rs 35 to treat mild to moderate Covid cases in India.
Sun Pharma – Revenue Model
It is reported that over 72% of Sun Pharma sales are from markets outside India, predominantly in the United States. Furthermore, the USA is the largest market area for Sun Pharma from where the company gets 30% of its total revenue from the USA markets. The revenue comes from its 44 global locations in India, the USA, Africa, Asia, Australia, and Europe.
Sun Pharma – Revenue Growth
Sun Pharma made a revenue of Rs 39,576 crores, which is equal to $5.0 billion in 2022. It had a net income of Rs 3,405 crores. It is reported that after deducting extraordinary items of Rs 3,935.7 crore and exceptional tax gain of Rs 76.4 crore, the adjusted net profit for the quarter was Rs 1,582.1 crore, which is up 18% year on year.
The contribution of Sun Pharma’s global specialty business has nearly doubled from 7% of consolidated revenues in FY18 to about 13% in FY22. Moreover, the company claims that in FY22, India formulation sales were at Rs 127 Billion, up 23%, and accounted for about 33% of overall revenues. Excluding the contribution of COVID products, the underlying business of Sun Pharma performed well, with about 20% growth over the previous year.
Sun Pharma – Investments
Sun Pharma has invested in four companies. Their investment is in Zenotech Laboratories, a pharmaceuticals company in India,which raised ₹53.2 million on March 21, 2022. Following is the list of investments by Sun Pharma:
Date
Company Name
Amount Invested
March 21, 2022
Zenotech Laboratories
₹53.2 million
September 10, 2018
Tarsier Pharma
$3 million
August 8, 2017
Krystal Biotech
$7 million
January 4, 2017
scPharmaceuticals
$45.6 million
Sun Pharma – Mergers and Acquisitions
Sun Pharma has bought seven companies. POLA-Pharma was their most recent purchase, which occurred on November 27, 2018. The acquisitions are:
Date
Acquiree name
Amount
November 27, 2018
POLA-Pharma
–
July 28, 2017
Zenotech Laboratories
₹855 million
November 23, 2016
OJSC Biosintez
$24 million
October 27, 2016
Ocular Technologies Sarl
$40 million
September 15, 2015
InSite Vision
$48 million
April 6, 2014
Ranbaxy Laboratories
$3.2 billion
November 9, 2012
DUSA Pharmaceuticals
$230 million
Sun Pharma – Advertisements and Social Media Campaigns
With a strong social media presence, Sun Pharma has launched multiple campaigns related to its brands. In 2021, Sun Pharma ran an advertisement about their brand Revital, titled: REVITAL H 21 Days Challenge with the #rahocharged. The advertisement features Bollywood Actor Akshay Kumar promoting their multivitamin supplement product Revital. The ad by Sun Pharma promotes taking up the 21 days challenge by having revital to feel energized in just 21 days.
During the pandemic, Sun Pharma released a thank you campaign titled: Sun Family Stands United With All Corona Warriors to extend their support to every frontier to stay united and fight against the Covid-19 pandemic.
Sun Pharma – Awards and Achievements
Some of the awards and milestones of Sun Pharma in recent years are:
2022
Sun Pharma was recognized as the No. 1 generic pharmaceutical company by patient groups in the annual PatientView ‘Corporate Reputation of Pharma’ survey 2021
Acquired the Uractiv portfolio from Fiterman Pharma in Romania
2021
Sun Pharma bagged the DIANA (Distribution Industry Award for Notable Achievements in Healthcare) award for ‘Best New Product Introduction/Promotion’
Sun Pharma received the Golden Peacock Award for Corporate Social Responsibility, 2020
Received the Best Innovative Company of the Year 2021 at Indo-American Corporate Excellence Awards.
Launched a specialty dermatology product called WINLEVI in the U.S. for topical treatment of Acne Vulgaris
2020
Sun Pharma was listed among the Forbes World’s Best Employers 2020
2019
Sun Pharma was ranked No. 1 in the pharma sector and No. 16 overall in the BW Businessworld list of India’s Most Respected Companies
Sun Pharma acquired Pola Pharma in Japan to strengthen its global dermatology presence
Sun Pharma Foundation for Disease Elimination and Control of India received the Mahatma Award for Social Good in 2019
2018
Sun Pharma received the Best CSR Practices Award from The Economic Times
Sun Pharma was listed among the Forbes World’s Best Employers
Sun Pharma – Competitors
Here is the list of top competitors of Sun Pharma:
Sun Pharma has mentioned in its future plans that its top focus area for FY23 is to ramp up its global specialty business. It also plans to have a business expansion that is both sustainable and lucrative. The company is planning to have a proper maintaining supply chain continuity while focusing on inventory management along with increasing investments in IT to allow business and digital transformation and to improve overall return ratios.
FAQs
Is Sun Pharma the top most Indian pharma company?
Yes, Sun Pharma is the top pharma company in India in terms of market capitalization.
Which is the most popular product by Sun Pharma?
Revital is among one of the most popular products by Sun Pharma.
Who is the CEO of Sun Pharma?
Kal Sundaram is the current CEO of Sun Pharma.
Where is the head office of Sun Pharma?
The head office of Sun Pharma is in Goregaon, Mumbai.
Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Piramal Enterprises.
If you were to start a business, you would require considerable time and effort to maintain the legacy. For businesspeople to run a business is not an easy job. It needs dedication and strategic planning to be successfully managed.
There are some entrepreneurs who like to take up challenges and diversify their businesses into multiple markets or industries. To put it simply, this type of business is called a conglomerate. As a matter of fact, India is home to many such conglomerates and over the past few years, it has witnessed some major developments with many growth-oriented policies.
In this article, we are going to share some the story of the Piramal Group, which is India’s leading global business conglomerate company. Headquartered in Mumbai, Piramal Group was founded by Ajay Piramal in 1984 with varied expertise in sectors like Pharma, Financial Services, and Real Estate.
Find out more about Piramal Group’s startup story, its key people, what are its marketing strategies, its revenue model, challenges faced, funding and investors, and many more in the article further.
Piramal Group is a multinational company with holdings in pharmaceuticals, healthcare information management, life sciences, financial services, and real estate. Started by Ajay Piramal in 1984, Piramal Group now has offices in almost 30 countries and a team of over 10,000 people working from various cultures and regions.
The Piramal Group works by offering diversified commercial services under different categories such as Piramal Enterprises Ltd. (PEL), Piramal Pharma Ltd., Piramal Realty, and Piramal Foundation.
Pfizer’s UK manufacturing site in Morpeth was purchased by the company in 2006. Piramal Group signed an agreement with Merck Pharmaceuticals in 2007 to collaborate on medication research and discovery. It secured a second medication research agreement with Eli Lilly and Company in 2008.
Piramal Group – Founder and Team
Piramal Group was founded by Ajay Piramal in 1984.
Ajay Piramal
Ajay Piramal is the Chairman of the Piramal Group. He was born on August 3, 1955, in Rajasthan, India to Gopikisan Piramal and Lalita Piramal. Ajay Piramal earned a bachelor’s degree in science from Jai Hind College and the Basantsingh Institute of Science at the University of Mumbai, and a master’s degree in management studies from the Jamnalal Bajaj Institute of Management Studies at the University of Mumbai. He also did a six-week Advanced Management Programme at Harvard Business School in 1992. He has been awarded an honorary doctorate by Amity University in India, as well as an honorary doctor of science by IIT Indore.
Ajay Piramal has received many awards and honors. To name a few, he received the Honorary Commander of the Order of the British Empire (CBE) in 2022 for services to the UK-India trade relationship, Business Leader of the Year Award 2018, CNBC Asia’s India Business Leader of the Year Award 2018, Outstanding Philanthropist 2013 and 2014, Forbes Philanthropy Awards, Special Achievement Award, Asia Pacific Entrepreneurship Awards (APEA) 2018 and many more.
Ajay Piramal plays many roles. He is the Non-Executive Director of Tata Sons Ltd. In addition, he is on the Board of Advisors at India’s International Movement to Unite Nations. He has remained an invitee to the World Economic Forum for the last 20 years.
Ajay Piramal’s wife is Dr. Swati Shah Piramal, who is the Vice Chairperson of Piramal Group. They have two children. Nandini Piramal D’Young, their daughter is married to US citizen Peter D’Young. Anand Piramal, their son, is married to Isha Ambani Piramal, daughter of Mukesh Dhirubhai Ambani, and his wife Nita Dalal Ambani. Ajay Piramal’s net worth was projected to be $3.7 billion as of June 2022.
Dr. Swati Shah Piramal
Born on 28th March 1956, Swati Shah Piramal is an Indian Scientist and Industrialist, and the Vice Chairperson of the Piramal Group. In 2012, the President of India awarded her the Padma Shri, one of India’s highest civilian accolades, for her contributions to the scientific and technology industries.
Dr. Swati Piramal was the first woman to serve as President of India’s Apex Chamber of Commerce. Along with this, she is also a member of the Harvard Board of Overseers and the Dean’s Advisor to Harvard Business School and the Harvard School of Public Health.
She has founded Mumbai’s Gopikrishna Piramal Hospital and has led public health initiatives against chronic diseases such as osteoporosis, malaria, tuberculosis, epilepsy, and polio.
Dr. Swati Piramal has a medical degree from Mumbai University. She holds her master’s degree from the Harvard School of Public Health. For her various outstanding contributions to healthcare and philanthropic movements, Dr. Swati has been the recipient of many accolades. BMA Management Woman Achiever of the Year Award (2005), Nominated for the Forbes Philanthropy Awards 2013 in the Outstanding Philanthropist category, Listed in the 25 Most Powerful Women, and is now a part of the Hall of Fame of Most Powerful Women among many others.
Piramal Group – Mission and Vision
The mission statement of Piramal Group is, “We aim to serve our customers, community, employees, partners, and all other stakeholders by putting their needs and well-being first”
Piramal Group stays true to its following core values:
Knowledge
Action
Care
Impact
Piramal Group – Name, Tagline, and Logo
Piramal Group is named after the surname of the Piramal family.
The logo of Piramal Group was designed by taking inspiration from ancient times, which is the universal symbol of the Gyan Mudra. The symbol Gyan Mudra is often practiced in yoga, dance, and meditation. As seen, it displays a hand doing the mudra with each finger symbolizing one of the five elements – Air, Water, Earth, Fire, and Sky.
The tagline of Piramal Group is, “Doing Well and Doing Good”
Piramal Group – Business & Revenue Model
Piramal Group is a conglomerate industry whose business is divided into three major segments – Real Estate, Pharma, and Financial Services. It provides diversified commercial services. The firm operates its business in 30 nations, as well as has a worldwide brand presence in over 100 markets.
Piramal Group’s biggest business is its Piramal Enterprises Ltd. (PEL). PEL recognized an opportunity to develop its pharma business and invested in the local formulation sector while the Indian pharmaceutical industry was focused on overseas generics.
Piramal Enterprises Ltd, Piramal Realty, and Piramal Foundation are the three main components or part of the Piramal Group business.
Here’s taking a brief look into the business segments of Piramal Group:
Piramal Enterprises Limited –
Previously known as Piramal Healthcare Ltd., Piramal Enterprises Ltd. accounts for the largest company of the Piramal Group.
It is further divided into two categories –
Piramal Financial Services
It is active in business verticals by offering financial services such as
Piramal Capital & Housing Finance Limited (PCHFL) – It is a home financing corporation registered with the National Housing Bank (NHB) and involved in a variety of financial services companies. It offers wholesale and retail finance alternatives across industries. It also has customized financing solutions for the hospitality sector.
Piramal Alternatives (PA) –It offerscustomized finance options for high-quality corporations seeking to enhance their growth.
Piramal Credit Fund (PCF) – PCF is a sector-agnostic fund that has received a significant capital commitment from CDPQ (Caisse de dépôt et placement du Québec) to invest in mid to large-sized corporations across industries.
India Resurgence Fund (IndiaRF) –By taking a flexible strategy approach, IndiaRF is an equal joint venture between Piramal Enterprises Limited and Bain Capital Credit. It invests capital in the form of both loans and equity, in distressed to control circumstances in the Indian market. It has a dedicated website for IndiaRF – www.indiarf.com
Piramal Pharma Ltd. (PPL)
The Piramal Group’s Piramal Pharma provides a range of specific goods and services with the latest technological advanced manufacturing capabilities that are spread over 15 locations and a global distribution network in over 100 countries. It has services such as Pharma Solutions (the manufacturing unit),Critical Care (Complex Hospital Generics business), and Consumer Products Division (CPD) which sells over-the-counter medications. The company is also engaged in the ophthalmic category by teaming up with Allergan India. It is one of the leading specialty pharmaceutical companies in the ophthalmic category that offers high-quality medication and devices to treat diseases such as glaucoma, eye infections, and inflammations.
Piramal Realty
The Piramal Group ventured into the business of Real Estate in 2012 under the brand name Piramal Realty. It has architectural innovators KPF, HOK, Callison, Fosters, and Make among their collaborators, as well as worldwide structural consultants like BuroHappold, security and transportation specialists Max Security, and vertical transportation experts Lerch Bates.
Piramal Realty’s mission reads, “To build India’s most admired real estate company, admired not just for its scale & profitability, but also for its impact on the lives of its customers & the progress of our country.”
Piramal Realty’s top projects are – Piramal Mahalaxmi, Piramal Aranya, Piramal Agastya, Piramal Vaikunth, and Piramal Revanta.
Piramal Foundation
The company is vested in many philanthropic activities for which it established the Piramal Foundation in 2006. The foundation is actively engaged in the following projects:
Piramal Swasthya is a Karnataka-based health information helpline service named Arogya Vani.
Piramal Sarvajal, solar-powered water ATMs supply clean water in India.
Piramal School of Leadership provides education and women empowerment through the program – Piramal Fellowship and Principal Leadership Development Program (PLDP), Pratham delivers education to underprivileged children
Piramal Prize to recognize emerging organizations
Piramal Group – Revenue Growth
As of 2022, Piramal Group reported revenue of $1.8 billion (Rs 14,710 crores). The net income of the company stood at around $240 million (Rs 1,923.11 crores). The company generates about 40% of its revenue from outside the country.
Piramal Group – Funding and Investors
Piramal Enterprises has raised $737.1 million in three rounds of investment. Their most recent funding came from a Post-IPO Equity round on June 27, 2020. Their funding is supported by three investors. The most recent investors include The Carlyle Group and Standard Chartered Bank.
On December 18, 2019, Piramal Group raised $225 million in a single venture vehicle called India Resurgence Fund. The details are:
Date
Funding Round
Fund Amount
Investors
June 27, 2020
Post-IPO Equity
$490 million
The Carlyle Group
July 21, 2019
Post-IPO Debt
₹15 billion
Standard Chartered Bank
July 15, 2019
Post-IPO Debt
₹2 billion
Sachin Bansal
December 18, 2019
–
$225 million
Single Venture fund
Piramal Group – Mergers and Acquisitions
Piramal Enterprises has bought 5 businesses. On September 29, 2021, they acquired Dewan Housing Finance. They paid 3.8T for Dewan Housing Finance. Piramal acquired 11% of Vodafone Essar in 2011-12. The company sold its 11% stake in Vodafone India to Prime Metals, an indirect subsidiary of Vodafone Group, in 2014. The acquisition details are:
Date of Acquisition
Acquiree name
Amount
September 29, 2021
Dewan Housing Finance
₹3.8T
March 31, 2021
Hemmo Pharmaceuticals
₹7.8B
May 12, 2017
Walnut Medical
Undisclosed
January 31, 2017
Mallinckrodt – Specialty Products $170 million
August 16, 2016
Ash Stevens
$53 million
1999
Ceylon Company Limited
–
1984
Gujarat Glass Limited
Undisclosed
Piramal Group – Investments
On August 11, 2014, Piramal Enterprises invested in VGN Property Developers. This investment, Venture Round – VGN Property Developers, was worth $3 billion.
VGN Property Developers is a multibillion-dollar real estate firm based in Chennai.
Piramal Group – Advertisements and Social Media Campaigns
Piramal Capital and Housing Finance Ltd. (PCHF) launched a campaign in 2019 about their service called Bridge Loans. It is an ingenious tool that aids in the transition from selling an old house to purchasing a new one. Point of View Brandcom India is behind the concept of the advertisement. The ad shows how a person finds an apartment for his family but keeps the owner of the apartment waiting until he sells his old apartment.
Here’s what Mayank Jain, Head of Sales & Marketing at Piramal Capital & Housing Finance said about the campaign, “We at PCHF are focused on introducing products that seek to simplify the lives of our customers. A common problem that we encounter regularly is the wait to sell your old apartment to buy a new one. Our newly launched product – Bridge Loans is the answer to this problem. Through the film, we aimed to highlight this challenge and bring focus to our innovative product, specially designed to support our customers’ needs. We are pleased that Point of View Brandcom India has converted our brief into an effective product film by using humor to communicate our product offerings.”
Piramal Group – Awards and Achievements
Below is the list of the latest awards and achievements won by the Piramal Group:
Piramal Pharma recognized with the “2019 Global Customer Service Leadership Award” by Frost & Sullivan
Piramal Foundation recognized as ‘Socially Aware Corporate of the Year by Business Standard CSR Awards 2019
Piramal Capital & Housing Finance recognized as ‘Outstanding Company in Infra Finance’ at the 8th EPC World Awards
Piramal Realty was awarded the prestigious ‘Intelligent Enterprise Award 2018’ by Technology Senate in Pune on June 7, 2018
Piramal Housing Finance was recognized as the ‘Emerging Home Loans Provider of the Year at the MCHI CREDAI Golden Pillar Awards 2018 in Mumbai on May 5, 2018
Piramal Realty was conferred with the prestigious Mercer NDTV Employer Excellence Awards for ‘Excellence in Work-Life Balance’, in New Delhi on May 2, 2018
Piramal Glass USA was recognized as the ‘Suppliers of the Year 2018’ at TricorBraun’s 2019 Annual Sales Meeting & Supplier Showcase in St. Louis on January 23, 2019
Piramal Housing Finance was recognized as the ‘Emerging Home Loans Provider of the Year at the MCHI CREDAI Golden Pillar Awards 2018 in Mumbai on May 5, 2018
Piramal Pharma Solutions was recognized in all six categories including Capabilities, Compatibility, Expertise, Quality, Reliability, and Service at the recent CMO Leadership Awards, New York on March 21, 2018
The Piramal Group is targeting to expand its financial services by adding 100 branches in FY23. The firm is all set to launch different and high-yielding products and aims to strengthen its partnerships with fintech and consumer tech firms. With their recent acquisition of debt-ridden DHFL, the company is planning to go for low-cost acquisitions.
FAQs
Who is the CEO of Piramal Group?
Peter De Young is the CEO of Piramal Group.
How much is Ajay Piramal worth?
The net worth of Ajay Piramal is 940 Crores.
Where is the head office of Piramal Group?
The head office of Piramal Group is in Mumbai.
How many companies are there under the Piramal Group?
Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Petpooja.
The relationship of Indians with their food is intimate. The food here in India is an emotion that also reflects the country’s culture and its personality. One can be amazed by the vast variety of food items India has to offer as each State has its version of edible items.
Indian culture beholds the extensive and rich food culture as well. Due to the infusion of a wide list of delicacies, the concept of the restaurant business has also taken over all of India. Today, we have thousands of food chains, hotels, and restaurants offering numerous different dishes based on a variety of cuisines.
While food is not only limited to India but is an important aspect in most countries. The food business has widely become popular in almost all parts of the country. To help with this restaurant business some companies manage and help organize unorganized food and beverage sectors.
Petpooja is one such company that offers restaurant management software for the F&B retail market. The company was founded in 2011 and is headquartered in Ahmedabad, Gujarat.
Discover more about Petpooja’sstartup story, how it works, industry details, founder, competitors, challenges faced, and future plans.
The lack of appropriate technology in the F&B sector is what motivated the founders of Petpooja to come up with one of the top restaurant management software to help give them a smooth experience management experience.
Petpooja is the leading next-generation PoS platform for the F&B industry. The company’s legal name is Prayosha Food Services Pvt. Ltd.
Its PoS system runs all of its client’s operations smoothly, allowing its customers to focus on other functions to further expand its restaurant business. The company has over 35,000 clients across India, the UAE, and South Africa.
The PoS system of Petpooja involves a billing system, inventory management system, reporting, customizable menus, CRM, and online ordering.
Petpooja flatters itself to be present in more than 140 cities not only in India but also in UAE. It has employed more than 750 people across the globe.
The Petpooja platform processes over 200,000 invoices each day and receives over 50,00,000 API requests every day. The platform is independent of the operating system (Windows, Mac, or Linux) and the browser. Node.JS, Python, PHP, Adobe, MySql, MongoDB, SqlLight, and ReactJS are among the technologies used on the platform.
Petpooja works with companies and organizations like Dunzo, IIFL, Bank, PayTM, HDFC NPCI, Zomato, and Swiggy, and by partnering with around 300+ restaurants.
Petpooja – Industry details
The worldwide food and beverage industry is predicted to rise at a compound annual growth rate (CAGR) of 9.7% from $5,817.4 billion in 2021 to $6,383.49 billion in 2022. The food and beverage industry is predicted to increase at an 8.7% CAGR to $8,905.5 billion in 2026.
With this increased rate there could be exponential growth for cloud-based restaurant management platforms like Petpooja, which provide operational needs to any kind of F&B outlet.
Petpooja – Founders
Petpooja is founded by Parthiv Patel and Apurv Patel.
Apurv Patel (left) & Parthiv Patel (right)
Apurv Patel
Apurv Patel is the Co-founder and CSO of Petpooja. He has a degree in B.E degree in Electronics & Communication from Sardar Patel University. Before founding Petpooja, Apurv worked in many organizations by engaging himself in different roles. He started out working as an Executive Assistant at Claris Lifescience, then working as a Business Analyst at Elitecore Technologies, etc. Apurv Patel is a people person and always advises to remain ethical and transparent while doing business.
Parthiv Patel
Parthiv Patel laid the foundation stone of Petpooja along with his friend Apurv Patel. Prior to beginning the journey of Petpooja, Parthiv has been associated with many companies. To be precise, he began his career as a Senior Project Engineer at Wipro Technologies to then worked as an Associate Vice President at GVFL.
PetPooja – Startup Story
The founders of Petpooja – Apurv Patel and Parthiv Patel started Petpooja with the mindset of making the unorganized sector of the F&B industry into a more systematic and methodical sector. The due were school friends, who reunited one single day to end up discussing their love for food in Ahmedabad city. This is one of the biggest reasons before starting Petpooja.
In the initial days of Petpooja in 2011, it started as a delivery service for corporations and multinational corporations. They served as a go-between for its partner restaurants to deliver huge bulk orders of corporate meals. Within two years, Petpooja made considerable progress by servicing over 200 corporate clients in Ahmedabad and partnering with 300+ eateries.
During the delivery process, the duo realized that they had to put a lot of effort to carry out the process, which involved orders, constant follow-ups, inventory and orders and bills, and a lot more other things. Keeping up with the pace of manually taking orders is what pushed the founders to take appropriate technological help. They sought to automate the monotonous and repetitive processes, giving the restaurant owner more time to focus on customer care and business success.
After pitching the idea of embracing Petpooja Point-of-Sale (PoS) software, the company raised its funds and achieved a positive outcome. It grew from a two-member team to over 200 employees in 2019. Gradually, the company upgraded its software by adding features like Kiosk, AI-enabled software, and FoodBot, which is a Robot that does the serving chores of a waiter in a restaurant.
PetPooja – Mission and Vision
The mission of Petpooja says, “Our mission is to be the go-to Operating System for all F&B retail across the world”
The company relies on four philosophical visions:
Pricing
Simplicity
Innovation
Support
PetPooja – Name, Tagline, and Logo
Petpooja’s logo is the company’s name itself.
PetPooja – Business Model
The business model of Petpooja can be said to have a B2B2C model. Since Petpooja provides restaurant management software solutions to a majority of restaurant business owners, it offers a complete product or service transaction process. The business model of the company allows mutually beneficial service or product delivery channels through its PoS system.
Petpooja operates its business by offering PoS systems that have a complete system for an online operation that eases the operations of many restaurant owners. The services include –
Billing system – Deskstop billing software allows the customers to manage high-order bills in a smooth manner. The software is operational on any device, be it a laptop, desktop, tabs, or any touchscreen electronic device.
Inventory Management Software – This software by Petpooja allows customers to manage their entire restaurant stock such as raw materials to even monitor semi-prepared items on the kitchen module system. Petpooja inventory app gives its clients the liberty to keep their stock list updated in a matter of minutes and automatically sync all the data to Petpooja’s cloud.
Reporting – Whether it is tax, an email report, a cancellation report, or other bill reports are all stored under the simplified reporting dashboard to give its customers a glance at important reports in one place.
Menu Card Dashboard – Petpooja also gives the liberty to its clients to add their restaurant menus. The feature also allows them to customize as per their food items’ availability. In addition to this, it also has special notes for the restaurant owner’s customers to allow them to give special instructions.
CRM – This service by Petpooja allows its clients to engage and track their loyal customers to help build healthy relationships. Petpooja’s Feedback Management System lets its clients collect feedback and other suggestions from their customers either through SMS links, QR codes, or using tablets or mobile phones.
Online order integration – The PoS of Petpooja offers seamless online order management. Companies like Zomato, Swiggy, and Amazon use Petpooja’s online order management system.
Apart from offering this above-mentioned software, Petpooja also gives the option to add features to its client’s existing PoS system. The Petpooja App marketplace further optimizes its clients’ PoS system with special apps and other services.
Besides, Petpooja has other tech products like Waiter Calling Device, Captain App, and Tvito: the marketing app.
Petpooja PoS system is widely being used by F&B outlets like Fine Dine, Cloud Kitchens, Bakery, Bar, Canteens, Food courts, Pizza shops, Cafes, and other large chains.
PetPooja – Revenue Model
After relaunching with the PoS system, Petpooja gained a good amount of revenue. With a new approach to the business model, Petpooja slowly picked up the race and built its business into a more scalable one. The initial years for Petpooja were tough but now the company has made a total revenue of $126 million.
The two streams from which Petpooja generates its income are:
Petpooja App Marketplace by offering add-on features and other integrations.
Through online and credit card transactions.
PetPooja – Funding, and Investors
Petpooja has received $8.9 million in investment over three rounds. Their most recent funding came from a Series B round on November 15, 2021. The company is supported by five investors. The most recent investors are GVFL and Mayur Desai.
Date
Funding round
Lead Investors
Funds raised
November 15, 2021
SERIES B
Aroa Ventures
$4.5 million
February 10, 2020
SERIES A
Udaan
$140 million
November 16, 2019
SEED Round
Trustroots
$2.4 million
PetPooja – Growth
The growth of Petpooja can be said to be commendable as the company today works closely with big companies like Havmor, Jumboking, Apsara, TGIF, The Beer Cafe, Thalappakatti, and many more. From starting as a delivery service to now climbing to offering innovative software services to various businesses, Petpooja has come a long way.
Presently, the company has a strong and expanding family of more than 800 people, and it has begun scaling its operations overseas as well. The $4.5 million Series-B fundraising recently will help the company to pursue its ambition to disrupt the restaurant-tech enterprise and enhance the efficiency of all eateries and F&B models.
During the pandemic, Petpooja came up with unique features to help many businesses, which were shut down due to lockdown in 2020. The company came up with ideas to help businesses recover from the pandemic and cope with losses in a more useful way. It launched robust features such as Scan-Order-Pay, Voice-ordering Kiosk, Petpooja Restaurant Analytics Insights, SMS service, Online Order Reconciliation, Suppliers Hub, etc.
PetPooja – Advertisements and Social Media Campaigns
Petpooja has its own App called Tvito, which is a marketing app designed for restaurant owners to help them create social-media-worthy pictures. The mobile app – Tvito offers 50,000+ designs, 20+ cuisines, and vast options for content creation to promote any restaurant business.
To promote the launch of Tvito, Petpooja posted a video showcasing the various features of Tvito on its YouTube Channel.
PetPooja – Competitors
Some of the competitors of Petpooja are:
Repeat App
myHQ
FoodDocs
POSist
SlickPOS
Toast
Urban Piper
Vend POS
LimeTray Restuarant POS
GloriaFood
PetPooja – Future Plans
Petpooja’s main aim is to become the country’s one-stop solution for an operating system for all F&B outlets across the world. The company’s innovative and smart products and services have made them one of the leading PoS software companies in the country today.
FAQs
When was Petpooja founded?
PetPooja was founded in 2011.
Who is the founder of Petpooja?
The founder of PetPooja is Parthiv Patel.
Where is the headquarters of Petpooja?
PetPooja is headquartered in Ahmedabad, Gujrat.
Does Petpooja serve only in India?
No, the services of PetPooja are available in UAE & South Africa as well.
Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Biocon Limited.
The healthcare marketplace is drastically evolving with many therapeutic solutions. Biopharmaceutical is one such discovery in the healthcare sector that is treated as one of the most significant achievements in modern science and technology. The biopharmaceutical industry is different from pharmaceutical startups in terms of the manufacturing process.
Biopharmaceutical products or medicines are manufactured in or, extracted from living organisms or biological sources, unlike pharmaceuticals, which are manufactured using chemical substances.
Known as an international pioneer, Biocon Limited, is an Indian biopharmaceutical firm founded by Kiran Mazumdar-Shaw in 1978. The company is based in Bangalore, India, and produces generic active pharmaceutical ingredients (APIs) that are distributed in over 120 countries worldwide.
Founded in 1973, Biocon Limited produces both new biologics and biosimilar insulins and antibodies, and generic APIs across the globe covering more than 120 countries, the major being the USA and Europe markets. The company consists of a talented and dedicated workforce of 13,500 employees.
For 40 years, Biocon has been consistently creating a culture of continuous innovation with four global businesses such as – generics, biosimilars, research services, and novel biologics. Its research and development are focused on prevention, relief, treatment, and medicines to enhance the lives of millions of patients. They believe in offering affordable quality medicines for many people. It strives to give reasonable access to a specialty portfolio of medications to everyone, everywhere.
As a global brand, Biocon is leveraging economies of scale by consistently investing in the development of new treatments for diabetes, cancer, and immunology. Biocon’s subsidiaries are –
Biocon Biologics and Syngene International Limited (Syngene).
Biocon Limited – Industry details
The Covid-19 impact has led to the growth of the Biopharmaceuticals industry in recent times. As per records, the global biopharma industry market growth is expected to reach $26.49 billion in 2028. This growth will see a CAGR of 12.6% during the period from 2021 to 2028.
Biocon Limited – Founder and Team
Biocon Limited is founded by Indian billionaire entrepreneur, Kiran Mazumdar-Shaw in 1978.
Kiran Mazumdar-Shaw – Founder of Biocon
Kiran Mazumdar-Shaw
Awarded the EY World Entrepreneur Of The Year 2020 and the first woman to head the board of governors of the Indian Institute of Management Bangalore, Kiran Mazumdar-Shaw is an inspiration for many women. She was born to Gujarati parents on March 23, 1953, in Bangalore, Karnataka. Rasendra Mazumdar, her father, was the head brewmaster of United Breweries.
Kiran Mazumdar-Shaw attended Mount Carmel Institution in Bangalore, a women’s college affiliated with Bangalore University, where she studied biology and zoology, earning a bachelor’s degree in 1973. Listening to her father’s advice, Kiran went to Ballarat College, Melbourne University in Australia to study malting and brewing attaining a master’s degree in brewing in 1975.
Before Biocon, Kiran was a trainee brewer at Carlton and United Breweries in Melbourne, as well as a trainee maltster at Barrett Brothers and Burston. Between 1975 and 1977, she also served as a technical consultant at Jupiter Breweries Limited in Calcutta and as a technical manager at Standard Maltings Corporation in Baroda.
Kiran Mazumdar-Shaw has done many philanthropic activities such as the Biocon Foundation. Through this foundation, she has supported Arogya Raksha Yojana (Disease Protection Program/Health Help) and numerous other health and education programs. She has also supported the Bangalore Agenda Task Force, to improve the city’s infrastructure and standard of living.
Kiran Mazumdar-Shaw is the Chairperson of Biocon Limited. In her lifetime, she is the recipient of many prestigious awards. Just to name a few, she was conferred the prestigious Quality Ratna Award for the year 2020 by the Confederation of Indian Industry (CII), she was elected as a Fellow of the Royal Society of Edinburgh (RSE), Scotland’s National Academy, she received the Othmer Gold Medal in 2014 for exceptional contributions to the progress of science and chemistry. Kiran also received the Padma Shri in 1989 and the Padma Bhushan in 2005 from the government of India. Not to forget, she was ranked #68 on the Forbes list of the World’s 100 Most Powerful Women in 2020.
Kiran is married to John Shaw. He is a Scotsman and Indophile who was Chairman and Managing Director of a renowned textiles MNC Madura Coats before joining Biocon in 1999 and serving as Vice-Chairman and Non-Executive Director of Biocon for almost 22 years before retiring recently in July 2021.
Dr. Arun Chandavarkar
Dr. Arun Chandavarkar is the Managing Director of Biocon Biologics Limited. He formerly served as the CEO and Joint Managing Director of Biocon Ltd. from April 2014 until November 2019, when he left after nearly three decades with the company. Before becoming CEO, he was the Chief Operating Officer of Biocon.
Dr. Chandavarkar earned a bachelor’s degree in chemical engineering from the Indian Institute of Technology (IIT) in Mumbai and a doctorate in biochemical engineering from MIT in Cambridge, Massachusetts. Under his management, the company has made significant investments in cutting-edge R&D and efficient, compliant operations, resulting in a distinct and differentiated product portfolio that includes fermentation-derived complex generics, biosimilars, and novel biologics aimed at a global patient population. For the 2016-17 fiscal year, Dr. Chandavarkar chaired the Confederation of Indian Industry’s (CII) National Committee on Biotechnology.
Siddharth Mittal
Siddharth Mittal is the CEO and Managing Director of Biocon Ltd. He has more than 20 years of comprehensive international expertise in strategic finance and accounting, mergers and acquisitions, taxation, and general management.
Siddharth Mittal was formerly Vice-President, Finance, and Corporate Controller at Symphony Teleca, a renowned US-based international IT business. He began his career in Bengaluru with the audit division of S.R. Batliboi & Co. (the Indian branch of Ernst & Young). He then worked for the US division of Xchanging Plc, an FTSE-listed firm located in London that specializes in business processing, technology, and procurement services.
Siddharth graduated from the Symbiosis College of Arts and Commerce in Pune with a Bachelor of Commerce. He is a Chartered Accountant from the Institute of Chartered Accountants of India and a Colorado Certified Public Accountant. Presently, he is also Co-Chairman of the CII Southern Regional Task Force on Pharmaceuticals and Co-Chairman of the CII Southern Regional Healthcare & Life Sciences 2020 – 21.
Biocon Limited – Startup Story
The story of Biocon started in 1978. It began as a joint venture with an Irish biotech business to develop and export enzymes for the brewing industry internationally. The company then gradually created a solid-state fermentation technique to manufacture innovative bio-enzymes for worldwide clients in the food and pharmaceutical sectors.
Unilever Plc purchased its Irish partners in 1989 and produced Biocon India as a member of the Unilever system, which allowed the company to quickly professionalize by adopting worldwide best practices.
In the 1990s, Syngene was established as a ‘pure play’ research services firm catering to the worldwide pharmaceutical industry’s R&D needs. Biocon moved beyond insulins to create monoclonal antibodies.
During its journey, Biocon found that most of the developing world couldn’t afford all the advanced therapeutic solutions. To support its purpose, Biocon raised capital through an IPO in 2004 and sold its enzymes business in 2007. Through constant research and developments, Biocon acquired a worldwide reputation as a genuine biosimilars player through a series of groundbreaking milestones, beginning with the approval of the world’s first bTrastuzumab in India in 2014 and the Japanese approval of bGlargine in 2016. It was the first in the world to receive approval in the United States for bTrastuzumab in 2017 and bPegfilgrastim in 2018.
Biocon’s investments on a global scale helped the company rank among the world’s top 15 biomanufacturing companies.
Currently, Biocon has emerged as one of the leading global biopharmaceutical companies with consolidated revenues of $1.1 billion (Rs 8,396.70 crores) and a more than 15,000 strong workforce.
Biocon Limited – Mission and Vision
Biocon’s vision statement reads, “To enhance global healthcare through innovative and affordable biopharmaceuticals for patients, partners, and healthcare systems across the globe.”
The company aims to deliver high-quality and reasonable healthcare products by prioritizing patients, focusing on science, and sustainable growth.
The mission of Biocon is, “To be an integrated biotechnology enterprise of global distinction”
Biocon Limited – Name, Tagline, Logo
The logo of Biocon can be seen to have a similar appearance to human DNA.
The overall tagline of Biocon as a company is, “Hope.saves lives.”
Biocon also has taglines for each of its subordinates:
Biocon Academy’s tagline is, “Adding Value, Enhancing Skills”
Biocon Limited – Business & Revenue Model
The business model of Biocon can be said to have five global business verticals – Generics, Biosimilars, Research Services, and New biologics, Research and development, and manufacturing of revolutionary biopharmaceutical medications. This developing paradigm is nicely linked with its business objective of offering inexpensive innovation. The company’s integrated business strategy encompasses the whole therapeutic value chain, from pre-clinical discovery to clinical development and beyond.
Biocon has three main business divisions that are its strength and backbone. This consists of – Syngene, Clingene, and Biocon, which are engaged in preclinical, clinical, and commercialization activities, respectively. Its business operations also involve the manufacturing of therapeutic areas such as Oncology, Diabetes, and Immunology.
Biocon’s business also includes developing enormous brand equity with physicians and patients by expanding its footprint into specialist sectors through which it earns its revenue. It has also produced medicines for Covid-19 such as – Alzumab-L, Dynalix, RemWin, etc.
Biocon’s CSR Activities
The company has no space when it comes to serving society. With its motto, “Driving Sustainable Social Change”, the company aims to be devoted to bettering lives and strengthening marginalized communities for a brighter future. The CSR initiatives of Biocon can be divided into two categories:
Biocon Foundation – Through this, Biocon has emphasized many healthcare solutions, providing for the environment and people through programs that promote social and economic inclusion. The company has set up eLAJ Smart Clinic platforms, an Oral Cancer Screening program, did a Community Vaccination Drive, supplied oxygen concentrators, Intensive Care Unit (ICU) monitors, digital X-Ray machines, ultrasound machines, pulse oximeters, and other medical equipment to support the COVID care infrastructure at the Anekal General Hospital and a lot more other social initiatives.
Biocon Academy – In conjunction with JSS University, Mysuru, Biocon Academy, helps to establish an ecosystem for biotech-related skills in India. The programs offered by the academy aim to provide advanced learning and industrial competence to life science graduates and post-graduates through job-skills development, which is required to create a rewarding career in the Biotech sector.
It recently launched a new course in Global Regulatory Affairs. The Academy was established 8 years ago. Till now, more than 850 students have enrolled in the academy.
Biocon is involved in offering many sustainable activities to provide a rewarding workplace through the EHS management system and to improve ESG (Environmental, Social, and Governance).
Biocon Limited – Revenue & Growth
As per reports, Biocon’s consolidated revenues increased 14% year on year to Rs 83,967 million, led by Biosimilars and Research Services revenue increases of 24% and 19%, respectively. Furthermore, for the fiscal year, Biosimilars earned Rs 34,643 million, Generics earned Rs 23,409 million, and Research Services earned Rs 26,042 million.
The company also claimed that its EBITDA climbed 14% year on year to Rs 21,829 million, with a respectable margin of 26%. Core EBITDA for the year increased 18% to ‘26,690 million, representing a margin of 32% after adjusting for licensing, forex, gain on dilution in Bicara, mark-to-market loss on investments, and R&D expense. Biocon’s net profit was $6,484 million. Certain extraordinary events, mark-to-market losses on investments, and a gain on dilution in Bicara all influenced net profit. After adjusting for these things, Biocon managed to increase its Net Profit by 23% for the whole year.
Biocon has announced that in FY22, Biocon Biologics increased its sales by 24% over the previous year, to Rs 34,643 million, with interchangeable bGlargine achieving double-digit market share in the United States, as well as ongoing improvement in the market share of other major existing products.
Biocon also saw some growth in its business segments. Syngene increased its bio-manufacturing capacity by commissioning a cutting-edge microbial facility and expanding its mammalian plant. Besides this, Biocon Biologics successfully progressed two unpartnered antibody projects to the clinical stage, bUstekinumab and bDenosumab.
Biocon Limited – Funding and Investors
Biocon Biologics has raised $24.4 billion in funding over four rounds. Their most recent fundraising came on January 7, 2021, in the form of a Venture Series Unknown round. Biocon Biologics is supported by four investors. The most recent investors are ADQ and Goldman Sachs.
Date
Funding Round
Fund Amount
Investors
January 7, 2021
Venture Round
₹5.6 billion
ADQ
November 9, 2020
Private Equity Round
₹11.3 billion
Goldman Sachs
July 31, 2020
Private Equity Round
₹2.3 billion
Tata Capital
January 6, 2020
Private Equity Round
₹5.4 billion
True North
Biocon Limited – Mergers and Acquisitions
On February 28, 2021, Biocon Biologics bought Viatris Biosimilars. They paid $3.3 billion for Viatris Biosimilars. Viatris Biosimilars is a USA-based company that has primary areas of focus on Oncology, immunology, endocrinology, ophthalmology, and dermatology.
On September 16, 2021, Biocon Biologics Limited (“BBL”) entered into a merger cooperation agreement with Serum Institute Life Sciences Private Limited (“SILS”) and Covidshield Technologies Private Limited (“CTPL” or Transferor business), a fully owned subsidiary of SILS.
Biocon Limited – Advertisements and Social Media Campaigns
In 2020, Biocon Biologics released a series of videos with the #StoriesofHope. The campaign was launched on Women’s Day to share the stories of two women who have survived deadly diseases like cancer and breast cancer.
Biocon Limited – Awards and Achievements
Here’s is the list of Biocon’s awards and recognitions in the last few years:
2022
Biocon Group Communication Team moved up to no.6 among 30 Top Corporate Communication Team Nationally
Biocon Biologics was conferred with the prestigious Legal Era Award, “Pharmaceutical In-House Legal Team of the Year” for 2021-22
Biocon Biologics was conferred with the coveted ‘20th Annual Greentech Safety India Award 2021’ during the Safety India Summit.
2021
Biocon won the ‘UN Women India WEPs Awards – 2021’in the “Transparency and Reporting”
Biocon made it to the Top 15 Indian Companies in the Emerging Market Index of Dow Jones Sustainability Indices (DJSI)
Biocon Biologics received the ‘Unnatha Suraksha Puraskara’ on September 9, 2021, by the National Safety Council (NSC), Karnataka Chapter.
2020
Biocon was recognized at the ‘UN Women 2020 India WEPs Awards’ for promoting a Gender-Inclusive Workplace and Gender-Responsive Marketplace amidst COVID-19.
Biocon Limited was ranked among the Top 5 Global Biotech Employers for 2020
Biocon bagged the ‘Best Biotech Patents Award 2018-19’ by Indian Drug Manufacturing Association (IDMA)
2019
Biocon won 2 awards at the TISS-Leapvault CLO Summit: ‘Learning and Development Team of the Year’ and ‘Best Diversity & Inclusion Program’.
Biocon moved up to Rank No. 6 on Science Careers’ Top 20 Global Pharma and Biotech Employers List 2019.
Biocon showcased a strong presence at Bengaluru Tech Summit 2019 for which it won the ‘Best Exhibitor Award’.
2018
Biocon Foundation, the CSR arm of Biocon Ltd. and Syngene International Ltd., was felicitated with SABERA Awards in New Delhi.
Biocon was honored at Pharmexcil Outstanding Exports Award 2017-18 for outstanding contribution to India’s Pharmaceutical Exports during the year 2017-18.
Biocon was honored with the prestigious IDMA Corporate Citizen Award in 2017.
Right now, Biocon’s main focus is to expand its diverse product portfolio to become a trustworthy global brand. The company plans are gaining global leadership by utilizing its size and cost advantages. it is further building a company with flawless quality compliance, world-class ethics, and a strong corporate governance framework. Through digital and data analytics, it plans to get closer to patients and reach a broader patient base. It believes that its three business categories, Generics, Biosimilars, and Research Services, are all well positioned for future expansion.
FAQs
Who is the CEO of Biocon?
Siddharth Mittal is the CEO of Biocon Limited.
Who is the founder of Biocon?
Kiran Mazumdar Shaw is the founder and executive chairman of Biocon.
Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Atlassian.
Imagine the following: It’s 2002, Sam Raimi’s Spider-Man is now in theatres, the term “Facebook” has no meaning, and smartphones are nothing more than futuristic gizmos. However, two recent college grads in South Wales, Australia, are probably chugging a few drinks, unwilling to dress up for a job they don’t want to get up for, and in the middle of it all, a startup concept is simmering. Mind you, back then, startups were hardly household names in the US, much less in Australia.
College friends turned business partners, Mike Cannon-Brookes and Scott Farquhar founded Atlassian, a company that the Sydney Morning Herald referred to as “a tech giant nobody understands” just a few years ago. It was founded in an aspect of the market that was scarce in Australia at the time, and to top it all off, what it produced wasn’t particularly ‘sellable,’ as some may put it.
At present, Atlassian has more than 10 offices worldwide, employs over 7,000 people, and serves more than 200,000 clients. Today, 83% of Fortune 500 firms use Atlassian’s products. Because its history defies what you may refer to as “regular,” we might like to think of Atlassian as the Forrest Gump of startups.
Due to the COVID-19 outbreak, many businesses now operate online. This is made feasible by digital remote work tools, and one of the most popular tools used by businesses is project management software. Atlassian is a company that has made remote working more convenient and interesting.
Here’s the success story of Atlassian that covers all about the company, the Startup Story and Growth, its Products, its Competitors, its Revenue, its Business and Revenue Model, and more, you can check ahead!
Atlassian is a technology company based in Australia that creates tools for software engineers, project managers, and other application development projects. The corporation has its legal residence in the UK, its international headquarters in Sydney, Australia, and its US headquarters in San Francisco.
For teams, Atlassian is a dominant producer of software for communication, development, and ticket management. They are extending the collaboration power with solutions including Jira, Jira Service Desk, Jira Ops, Confluence, Bitbucket, Trello, and more.
The organisation is on a journey to unlock the power of every team thanks to its authentic principles, incredible culture, and steady revenue progress. Jira, a project-tracking platform that supports software teams in addressing internal issues and evaluating progress, is the product for which Atlassian is best remembered. HipChat, which enables employees to talk anonymously and in groups, and Confluence, a platform that makes it simpler for teams to collaborate, share projects, and communicate across both mobile and desktop devices, and Stride, a new workplace communication tool developed by the corporation, enables teams to interact effectively and achieve their goals as a group, are some other products of Atlassian.
In addition to having over 2,000 plugins for developers, Atlassian has over 200,000 customers, 7,000+ employees globally, and a commitment to contributing 1% of company ownership and profit to charity.
Atlassian – Industry
In 2021, the project management software market generated US$5,359.6 million in sales. The project management software market is anticipated to reach $20,420.6 million in revenue by 2032, expanding at a CAGR of 13.1% between 2022 and 2032.
Nearly 35% of sales in the whole business process optimization industry are presently made by software for project management. Using a set of integrated tools like task management, collaboration tools, budget management, and document management that are highly customizable based on enterprise business requirements, project management software incorporates features like planning, working collaboratively, supervising, and delivering a project.
The market is anticipated to grow significantly in the upcoming years as businesses use automated project management software to carry out fundamental project management duties and functions automatically.
In addition, all businesses, regardless of their size, are constantly utilising the advantages of enterprise project management to enhance productivity, increased communication, raise project quality, and lower total budget estimates.
Mike Cannon-Brookes – Co-founder and Co-CEO of Atlassian
Mike Cannon-Brookes is the co-founder and co-CEO of Atlassian, a collaboration software startup that assists teams in organising, debating, and completing shared work.
Mike is a board member of Zoox and a technology investor outside of Atlassian, with interests in software, finance, agriculture, and energy. He is a board member of Room to Read and has a solid commitment to giving back. Mike, a fervent advocate for sustainable energy, played a key role in the “Fair Dinkum Power” movement as well as Australia acquiring the largest lithium-ion battery in the world.
He earned a Bachelor of Science in Business Information Technology from the University of New South Wales in Australia and works as an adjunct professor there in the School of Computer Science and Engineering.
Scott Farquhar- Co-founder and Co-CEO of Atlassian
The co-founder and co-CEO of Atlassian, Scott Farquhar, is a developer of collaboration tools that aid teams in planning, debating, and completing shared work. A corporate philanthropy initiative called Pledge 1%, which aims to make the community a significant shareholder in every firm, was launched in 2015 with Scott’s assistance.
Along with co-founder and co-CEO, Mike Cannon-Brookes, Scott received the Ernst & Young award for “Australian Entrepreneur of the Year” in 2006 as the youngest recipient ever. The Australian Financial Review recognised Scott and Mike Cannon-Brookes’s “Australian Business Person of the Year” in 2016, and Forbes included them on their list of “Global Game Changers” in 2017.
Outside of Atlassian, Scott co-founded Skip Capital. This private investment fund concentrates on rapidly expanding technology firms and has a special interest in the nexus between big data and health. Scott graduated from the Australian University of New South Wales with a BSc in Business Information Technology.
Atlassian – Startup Story
We are all aware of startups in the year 2020. If you don’t work for one or have a close buddy who does, you’re living under a rock. However, when university grads Mike Cannon-Brookes and Scott Farquhar established Atlassian in 2002, the reaction they got from other tempting offers wasn’t as common. And it was virtually unheard of in Australia, a nation that was reluctant to catch on to the digital revolution.
Like many strong friendships, Mike and Scott’s cooperation began in college. At the University of New South Wales in 1998, they were both enrolled on the same scholarship fund. They formed an intellectual and ambitious friendship and collaboration. They were required to join one of the Australian corporations funding the programme, much like the rest of the program’s students.
Instead, they developed Atlassian.
The majority of startups receive funding from cash that is sought out from outside investors. After all, venture capital now constitutes a separate business. Scott and Mike decided against going in that direction.
They borrowed money to pay for their endeavour; $10,000 of it was put on credit cards. The majority of people who incur large amounts of credit card debt do not emerge as ground-breaking billionaires, but they have demonstrated that they are not typical of most people, much as Atlassian has distinguished itself from the majority of businesses.
This also applies to the way they promoted their new product. Instead of having a large sales team, Atlassian relies on online sales. Going to developer meetings and buying them beer with an Atlassian sticker on the bottle was the first marketing tactic.
Their marketing approach depended on offering a high-quality product at a competitive price and positive customer reviews. And it succeeded. That stayed the case when Atlassian took off. Even now, Atlassian only spent 19% of revenue on sales and marketing, a much lower percentage than other software businesses in a comparable position.
The name Atlassian is derived from the Greek mythological figure Atlas, a titan destined to hold up the heavens or sky forever.
The Atlassian logo represents two folks giving each other a high-five, a mountain that is ready for teams to climb, or even the letter A made up of two pillars supporting one another.
Atlassian’s mission statement says, “Atlassian believes in the power of teamwork. Behind every great human achievement, there is a team. From medicine and space travel to disaster response and pizza deliveries, our products help teams all over the planet advance humanity through the power of software. Our mission is to help unleash the potential of every team.”
Atlassian – Products
The following Atlassian-owned and operated products are included in the Atlassian product family, together with any associated web applications and mobile applications:
Atlassian Cloud Products
Jira Software
Jira Service Management
Jira Work Management
Confluence
Bitbucket
Atlassian Access
Atlassian Cloud Apps
Trello
Trello Power-Ups
Statuspage
Halp
Jira Align
Opsgenie
Atlassian Server / Data Center Products
Jira Software
Jira Service Management
Jira Work Management
Confluence
Bitbucket
Analytics for Confluence app (Data Center)
Crowd
Automation for Jira (Server and Data Center) and Icons for Jira (Server)
Its solutions may be utilised in many ways across various business activities within the same company since Atlassian has a mass market business model with a multi-sided market. The majority of its consumer segments reflect specific business operations rather than sectors. The firm has benefited from this by creating software ecosystems for different business segments, each of which represents a unique business function.
IT (JIRA Software, IRA Service Desk, Confluence, HipChat) – The JIRA suite, which includes JIRA Software and JIRA Service Desk, enables IT, teams to swiftly respond to the needs of their organisation by maintaining effective feedback channels (through the Service Desk) and enabling efficient and managed workflows (through the Software).
Marketing (JIRA Core, Confluence, HipChat) – Marketing teams may handle data and marketing materials using the company’s project management tools, such as JIRA Core and Confluence.
Legal (JIRA Core, Confluence, HipChat) – JIRA Core enables legal teams to produce and manage legal materials, such as contracts and policies, and Confluence can be used to share these materials.
Finance (JIRA Core, Confluence, HipChat) – JIRA Core is used to handle financial activities including procurement and financial reporting by some of the top financial institutions in the world.
Software (JIRA Software, BitBucket, Bamboo, Confluence, HipChat) – JIRA Software, the company’s main product offering, is designed to speed up software development. A few of the company’s other products, such as Bamboo and Bitbucket, are especially geared toward programmers and software engineers.
Atlassian – Revenue Model
Direct online sales through Atlassian’s website are the company’s only sales channel. It spends only 15% to 20% of its income on sales and marketing and lacks a sales force. Contrast this with the typical average of over 100% of sales spent by IT companies on marketing expenses during the first few years following an IPO.
Atlassian’s primary method of customer assistance is self-service; the website offers a variety of self-help resources, such as product manuals and live training. Additionally, it relies on the community by maintaining an experts programme that allows independent expert partners to sign up to help Atlassian clients while promoting their goods or services, as well as by providing a community Q&A forum where users can post questions that can be answered by other users or by Atlassian’s staff.
For individualised help, Atlassian provides enterprise support services that charge a fee and enable technical account management through direct contact with top engineers within the business.
The development and upkeep of an integrated platform that clients may utilise for a range of business operations is Atlassian’s primary activity.
The founders haven’t become less grounded as a result of their success. Within the first four years of operation, the Atlassian Foundation was established along with a commitment to contribute 1% of business profits, employee time, and stock to charitable organizations.
Mike, the founder, has personally donated USD 350 million to groups working to combat climate change. He aspires to be more than just a successful philanthropist and is convinced that Australian businesses must put sustainability at the forefront of their strategies going forward. Given how quickly infrastructures are developing, he believes that those with the power to bring about meaningful change ought to acknowledge their obligation and seize control before it’s too late.
Human relationships have always been the most important thing to the founders. What their brand initially set out to be gradually evolved into an image with certain ideals at its heart that was presented during a meeting in the early days of the firm.
The notion of a community emerged from the principles that guided Atlassian’s gradual expansion. The business turned into a community-powered engine and became incredibly people-centric.
Stephanie, the Head of Global Community at Atlassian said in an interview, “If you don’t invest in things, you can’t expect them to do well. The reason that we’re successful now is that we put our money where our mouth is, and there’s actually an investment being made by the company.”
FAQs
What does Atlassian do?
Atlassian develops software that helps teams to work together more efficiently. It provides collaboration, development, and issue-tracking software to teams.
Who founded Atlassian?
Atlassian was founded in the year 2002 by Mike Cannon-Brookes and Scott Farquhar.
Is Atlassian a public company?
Atlassian went public in the year 2015 and is listed on NASDAQ as TEAM.
Is Jira owned by Atlassian?
Jira is an issue-tracking product, developed by Atlassian. It allows you to plan, track, and manage your agile and software development projects.
Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Raymond.
India as a diverse land has a lot of colorful trends when it comes to textiles and apparel. Of course, the collapse of all hype at the dawn of the twentieth century brought a more sensible environment and a more solid view of the fashion industry.
As far as we know, the Indian Textile industry is a significant contributor to the country’s economy. The industry is providing one of the most fundamental needs of the community and has importance; preserving ongoing development for raising the quality of life. It has established itself as a self-sufficient industry that adds value at every stage of the supply chain right from the production of raw materials to the delivery of finished goods.
Raymond Group is an Indian textile and fashion industry headquartered in Mumbai, India. Raymond was founded in 1925 by Albert Raymond. The group makes suiting material and has a 31 million meter capacity for wool and wool-blend fabrics.
Check out a lot more about Raymond, its startup story, its founders and team, business and revenue growth, the challenges faced, and a lot more relevant information.
Incorporated in 1925, the Raymond Group is a diversified organization with most of its business activities in the textile and apparel industries. It also operates in a number of other industries, including FMCG, Real Estate, Engineering, and Prophylactics, in both domestic and foreign markets.
With the support of more than a billion customers, Raymond is renowned for providing its customers with top-notch products for the previous nine decades.
The company is the owner of clothing brands including Raymond, Raymond Premium Apparel, Raymond Made to Measure, Ethnix, Park Avenue, Park Avenue Woman, ColorPlus, Kamasutra, and Parx. All of the brands are sold through “The Raymond Shop” (TRS), which has a network of more than 700 retail locations in India and abroad in more than 200 cities. The brand also has its presence in tier IV & V cities.
Woolen textiles, Cotton, Wool blends, Linen, and Denim are just a few of the luxurious shirting and suiting fabrics that Raymond has to offer.
After entering the clothing, textile, and sexual wellness segment, in 1949, Raymond Ltd. made a foray into the engineering industry. With a market share of more than 25% of worldwide steel file production capacity in 2020 and a presence in more than 55 countries, JK Files and Engineering Ltd. holds the top spot as the industry leader. It was 2019 that saw the announcement of Raymond’s entry into the real estate industry as Raymond Realty with the theme of ‘Go Beyond’. The new business would invest 250 crores (about $36 million) to create mid-range and luxury housing units on 20 acres of land in Thane, a rising suburb of Mumbai.
Raymond has also strived to do something for society. ‘Beyond business’, is Raymond’s humanitarian activities that are designed to foster inclusive growth for the socially underprivileged.
JK Trust Gram Vikas Yojana – improve the quality of life in rural areas through a Cattle Breed Improvement Programme (CBIP)
JK Bovagenix – On July 20, 2016, a groundbreaking breeding program using in-vitro fertilization to produce selected indigenous cattle breeds went into effect.
Skilled Tailoring Insititute – to train unemployed women
Raymond Tailoring Hubs for skill development – located in Mumbai, Delhi, Bihta, Jamshedpur, Jaipur, Nashik, Villupuram, Ranchi, and Bengaluru.
Singhania Schools
Raymond – Industry
As mentioned earlier, the Indian Textile industry contributes a major chunk to the country’s economy. This sector is also one of the oldest industries in the Indian economy. It is reported that the Indian textiles market is expected to be worth more than $209 billion by 2029.
Raymond – Leadership
Gautam Vijaypat Singhania is the Managing director and Chairman of the Raymond Group.
Gautam Vijaypat Singhania
Born to an industrialist family, whose parents are Vijaypat Singhania and Ashabai Singhania, Gautam Vijaypat Singhania is the Chairman and Managing Director of the Raymond Group. He attended Cathedral and John Connon Schools as well as St. Mary’s School in Mumbai. In 1986, Gautam Singhania joined the JK Group of businesses owned by the Singhania family. Later, he joined the Raymond Group, where he rose through the ranks to become chairman in September 2000, and managing director in July 1999.
Nawaz Modi Singhania, a Parsi, is the spouse of Gautam Singhania. They have a daughter called Niharika.
According to a family agreement, Gautam Singhania has been given a 27% share of the business. A few years after taking over, he turned the business around and made it become a big success.
Raymond – Mission and Vision
Raymond likes to do business with one vision, that is, “Trust, Quality, and Excellence”
Raymond – Name, Logo, and Tagline
As we all are aware, the tagline of Raymond is, “The Complete Man”
The brand name was derived from Albert Raymond and Abraham Jacob Raymond, who were members of the Board of Directors of a Jewish industrialist company during the 1920s known as E.D Sassoon and Co. Formerly it was known as ‘The Raymond Woollen Mills” and then it was changed to just ‘Raymond’.
Raymond – Startup Story
The story of the world’s largest producer of suiting fabric, Raymond goes back to the year 1925. An elderly man by the name of Wadia had the foresight to establish a modest woolen mill in the backward region of Thane, Maharashtra, spurred on by the burgeoning need for apparel for soldiers in the Indian Defense Force. However, Wadia couldn’t manage the woolen mill and it was taken over by E.D Sassoon and Co. It was them, who renamed the company, ‘The Raymond Woollen Mills’
After some years, in 1944, Lala Kailashpat Singhania took over Raymond when he saw the potential in the brand for the coming future. His family, the Singhanias moved to Farrukhabad from the little village of Singhana in Shekhawati, one of the desert towns of northeast Rajasthan, in search of better opportunities. They had their own company called JK Cotton Spinning & Weaving mills Co., wherein they produced high-quality cotton clothes using only Indian raw materials, labor, and other methods to compete against England.
Post-independence, Kailashpat took Raymond to newer heights and put up a new manufacturing unit JK Files in 1950 to manufacture indigenous engineering files. In 1958, Raymond opened its first exclusive showroom in King’s corner, Ballard Estate in Mumbai.
In 1986, Park Avenue was launched by Raymond, a collection of stylish wardrobes for men.
Raymond opened its first international showroom in Oman in 1990. After one year, the brand launched a premium condom brand called, ‘Kamasutra’. With the founding of Raymond Aviation in 1996, the group entered the aviation industry. Corporate travelers in India can use the air charter services offered by Raymond Aviation.
In order to provide customers with a variety of semi-formal and casual clothing, the luxury casual wear brand Parx was introduced in 1999. 2008 saw the introduction of ready-to-wear clothing under the Raymond brand, which is currently known as Raymond Ready to Wear.
In 2016, the company launched a kind of fabric, which the company referred to as the Smartest fabric in the World – it was known as Technosmart. In the same year, Raymond opened a new office in Dubai. With 900 outlets in 500+ Indian towns and cities as of 2018, Raymond had experienced its fastest-ever retail expansion.
To combat COVID, Raymond came up with ‘Virasafe’, a highly effective anti-viral fabric. To produce PPE suits during the outbreak, the brand converted its garment plants.
Raymond – Business model
Raymond’s business involves a number of business models because it deals with several types of business including real estate and aviation. However, it does have a B2B business model as it manufactures one of the finest cotton and pure linen fabrics.
Here’s taking a look at the various businesses by Raymond Group:
Suit Business
It is commendable that in India, the woolen suiting fabric industry is dominated by Raymond, one of the largest vertically and horizontally merged producers of worsted suiting fabric in the world, with a market share of over 60%. This business has manufacturing plants at Vapi (Gujarat), Chhindwara (Madhya Pradesh), and Jalgaon (Maharashtra) with a manufacturing capacity of 38 million meters.
Garment Business
Raymond has three wholly-owned subsidiaries – Silver Spark Apparel Ltd (Suits), EverBlue Apparel Ltd. (Jeanswear), and Celebrations Apparel Ltd. (Shirts) for its garment business. The only Indian company having the know-how to create Full Canvas Suits is Silver Spark Apparel Ltd. The company’s products such as jeans, trousers, shirts, and suits are all exported to the USA, Europe, and Japan.
Shirt Business
Raymond is also engaged in the manufacturing of shirt fabrics, which are very renowned and the finest in India. At its advanced manufacturing facility in Kolhapur (Maharashtra), the operation has a capacity of 26 million meters and manufactures bottom-weight textiles and high-end cotton and linen shirts for well-known national and international brands.
Retail Business
Raymond opened its first-ever retail showroom in Mumbai at King’s Corner in 1958. Since 1958, the brand has been expanding aggressively with its various collections. Its retail presence makes up for the brand’s success. With over 2 million square feet of retail space split throughout its 1100+ locations in more than 380+ cities and towns, Raymond now has an unstoppable retail presence and is steadily expanding.
The brand has a portfolio of four Power Brands, including Raymond Ready-to-Wear, Park Avenue, Color Plus, and Parx, which makes them currently as of one of the top three branded clothing players in the menswear market.
Across all channels, including 257 Exclusive Brand Outlets (EBOs), 3,300 Multi Brand Outlets (MBOs) (via distributor network), 800 Large Format Store (LFS) chains, and top internet portals, there has been a tremendous increase in recent years.
Raymond created raymondnext.com, a one-stop fashion shop for all the brands under the Raymond umbrella, as its entry into the e-commerce market.
Denim Business
One of the first companies to introduce specialty ring denim in India is Raymond UCO Denim (a joint venture with UCO NV of Europe). Along with serving domestic markets, the company also serves consumers in the Americas, Europe, and Asia. The company has fabric manufacturing plants in Yavatmal, Maharashtra, and Sibiu, Romania, with a combined annual production capacity of 47 million meters. Raymond UCO Denim satisfies the expanding expectations of fashion-conscious consumers and has earned the recognition of top brands in both home and foreign markets.
Tools & Hardware Business
The company entered into the tools and hardware business in 1949. This industry sector is involved in the production, marketing, and distribution of hand tools, power tool machines, and accessories for power tool machines as well as the sale and distribution of precision-engineered parts for tools and hardware like steel files and drills. As of 2020, JK Files and Engineering Ltd. had the largest installed steel file manufacturing capacity, accounting for nearly 25% of the global capacity. JK Files & Engineering Ltd. boasts state-of-the-art production facilities in India that are ISO 9000-2008 certified and have a robust manufacturing capacity of 7.44 million dozen files and 13.2 million pieces of drills annually. Raymond has a market share of more than 60% by sales volume in Fiscal 2021 and is also the market leader in India’s files segment. It is also well-represented in Latin America, Asia, and Africa.
FMCG Business
Raymond is involved in the manufacturing of consumer goods through its associate company called, Raymond Consumer Care Private Limited. Raymond is steadily growing its presence in the category with leading brands like Park Avenue and KamaSutra in the market today.
Automotive Business
By acquiring a controlling interest in Ring Plus Aqua Ltd, a renowned Ring Gear & Flexplate manufacturer in India, Raymond entered the automotive components market. Ring Plus Aqua Ltd., a 1984 incorporation, has a close relationship with the global automotive industry thanks to its manufacturing facility for ring gears, water pump bearings, and flexplates.
Through its warehouses in Canada, the United States, and Germany, Ring Plus Aqua Ltd. also meets the JIT (Just-in-time) needs of its clients. Around 8.2 million Ring Gears, 3.9 million Water Pump Bearings, and 0.62 million Flexplates can each be produced annually by Ring Plus Aqua Ltd.
Real Estate Business
With Raymond Realty, the company entered into the Real Estate space. Each project under Raymond Realty is built on the tenet of “Go Beyond” and attempts to redefine every customer’s expectation. The company has an exclusive website for its realty business – www.raymondrealty.in
Some of the popular brands and services by Raymond Group are:
ColorPlus
Ethnix
Raymond
Raymond Fine Fabrics
Park Avenue
The Raymond Shop
SuperDrive
Kamasutra
Raymond Custom Tailoring
Parx
Raymond – Revenue Model
Raymond’s revenue for the fiscal year 2022 was Rs 50,000 crores. The largest contributors to the company’s revenue were branded clothing and textiles. However, the exact figures haven’t been published. In the fiscal year 2021, Raymond India reported revenue of more than 36 billion Indian rupees.
Raymond – Challenges Faced
As the company is mostly in the manufacturing space of finest fabrics and gets its revenue majorly from the textile business, it fears that the millennials might move away from the concept of textiles and fabrics. Today’s youth are focused on buying ready-made garments and don’t wish to invest in textiles or buy fabrics.
This is one of the biggest challenges the brand is facing and to keep up with the trends, it needs to come up with innovations to maintain its legacy.
Raymond – Mergers and Acquisitions
Raymond acquired J. K. Ansell Ltd on Aug 17, 2017. The rest of the details are undisclosed.
Raymond – Online and Social Media Presence
Raymond has a powerful online and social media presence. The brand has pages on almost all popular social media platforms.
Platform
Followers
Facebook Page
1,357K followers
Instagram Page
220K followers
Twitter Page
10.6K followers
LinkedIn Page
170K followers
Raymond – Advertisements and Social Media Campaigns
Time and again, Raymond has always come up with the best and heart-touching campaigns throughout its 90-plus years of journey. With its motto, ‘The Complete Man’ – Raymond has always shown the characters of a well-read man, a perfect father, an honest friend, and an obedient son, which highlights the true emotions a man can have in him. While the list of campaigns made by Raymond is long, the most recent one is Raymond’s Look Good Feel Good campaign.
This campaign was launched in June, where the brand highlights the joy of giving your old clothes. The campaign is done in association with Goonj, a non-profit organization that undertakes humanitarian aid. The brand asks its viewers to donate clothes and in exchange for their old garments, they will receive free trouser stitching from July 1st onwards.
Another campaign by the brand was rolled out in 2019 called #TailorYourStyle. The ad speaks about the fine tailoring done by Raymond which shows its rich heritage and aesthetic embodiment. The campaign was designed by Grey India. It mostly highlights the customization that customers can get as per their needs.
Raymond – Awards and Achievements
Here’s showing the list of all the major awards won by Raymond:
Raymond ‘The Complete Man’ TV commercial (husband-baby) won the “National Laadli Media & Advertising Award for Gender Sensitivity 2013-14”
Raymond has been placed at the top of the ‘Textile and Garment’ segment as the ‘Most Admired Companies in India 2013’ by Fortune magazine
Park Avenue has won the Best Design Concept of the Year Award for Innovative AUTOFIT Concept at Images Fashion Awards 2015.
Raymond has won the ‘Best Retail Store Design for Fashion Apparel brand” for Raymond Ready-to-wear store, Viviana Mall, Thane from Visual Merchandising & Retail Design Awards 2015.
Raymond has won the ‘Best Window Display 2015″ for the Colors Of Wool campaign from Visual Merchandising & Retail Design Awards 2015.
ColorPlus awarded for ‘Impactful Retail Design and Visual Merchandising’ – Asia Retail Congress 2013
EPC (Engineering Export Promotion Council) India “Export Excellence Award 2011-2012” for Hand Tools Exports in the category of Large Enterprise
Park Avenue Beer Shampoo has won a bronze at the WARC Strategy Awards 2014.
11th Realty Plus Excellence Awards – WESTMid Segment Project of the Year (2019)
Hindustan Times Real Estate Titans Awards 2020
FAQs
Which company owns Raymond?
Raymond group, a global conglomerate owns Raymond ltd.
Who is the Chairman of Raymond?
Gautam Hari Singhania is the chairman and MD of Raymond group.
How many brands does Raymond own?
Raymond owns 4 brands namely Park Avenue, Parx, Color Plus along with Raymond Ready to wear.
Who are its competitors of Raymond in India?
Raymond’s competitors in India are Siyaram’s & Grasim.
Ashwini
